MBX2319 vs. PAβN: Comparative Analysis of Potency in Reversing Antibiotic Resistance in Gram-negative Pathogens

Nolan Perry Jan 12, 2026 447

This article provides a comprehensive comparison of MBX2319 and Phe-Arg-β-naphthylamide (PAβN) as efflux pump inhibitors (EPIs) against multidrug-resistant Gram-negative bacteria.

MBX2319 vs. PAβN: Comparative Analysis of Potency in Reversing Antibiotic Resistance in Gram-negative Pathogens

Abstract

This article provides a comprehensive comparison of MBX2319 and Phe-Arg-β-naphthylamide (PAβN) as efflux pump inhibitors (EPIs) against multidrug-resistant Gram-negative bacteria. We explore their foundational mechanisms of action targeting Resistance-Nodulation-Division (RND) efflux pumps, detail methodologies for assessing in vitro synergy with antibiotics, address common experimental challenges and optimization strategies, and present a direct comparative analysis of their potency, spectrum, and cytotoxicity. Designed for researchers and drug development professionals, this review synthesizes current data to inform the selection and development of next-generation adjuvant therapies to combat antimicrobial resistance.

Understanding the Mechanism: How MBX2319 and PAβN Target Gram-negative Efflux Pumps

The Critical Role of RND Efflux Pumps in Gram-negative Antibiotic Resistance

Within the ongoing research thesis comparing the efficacy of novel efflux pump inhibitors (EPIs) MBX2319 and Phe-Arg-β-naphthylamide (PAβN), understanding the function and impact of Resistance-Nodulation-Division (RND) efflux pumps is paramount. These tripartite protein complexes, such as AcrAB-TolC in E. coli and MexAB-OprM in P. aeruginosa, are primary drivers of intrinsic and acquired multidrug resistance in Gram-negative pathogens. They actively extrude a wide range of antibiotics, biocides, and host-derived molecules, significantly reducing intracellular drug concentration. This guide compares the experimental performance of two leading EPI candidates, MBX2319 and PAβN, in potentiating antibiotics against RND-mediated resistance.

Experimental Protocols for EPI Potency Assessment

Broth Microdilution Checkerboard Assay

This standard protocol determines the Minimum Inhibitory Concentration (MIC) reduction of antibiotics in the presence of serial dilutions of EPIs.

  • Inoculum Preparation: Adjust bacterial suspension (e.g., E. coli AG100 or P. aeruginosa PAO1) to 0.5 McFarland standard (~1.5 x 10^8 CFU/mL) in cation-adjusted Mueller-Hinton broth (CAMHB).
  • Plate Setup: In a 96-well microtiter plate, create a two-dimensional checkerboard. Serially dilute the test antibiotic (e.g., ciprofloxacin, levofloxacin) along one axis and the EPI (MBX2319 or PAβN) along the other.
  • Dilution & Inoculation: Dilute the bacterial suspension to achieve a final inoculum of ~5 x 10^5 CFU/mL in each well. Final volume is typically 100 µL.
  • Incubation: Incubate plates at 35°C for 16-20 hours.
  • Analysis: Determine the MIC of the antibiotic alone and in combination with each EPI concentration. Calculate the Fractional Inhibitory Concentration Index (FICI) to assess synergy (FICI ≤ 0.5).
Ethidium Bromide Accumulation Assay (Fluorometric)

This functional assay directly measures efflux pump activity inhibition.

  • Cell Preparation: Grow bacteria to mid-log phase, harvest, and wash twice with PBS or assay buffer. Resuspend to an OD600 of 0.2.
  • Loading & Efflux: Load cells with ethidium bromide (EtBr, 1-10 µg/mL) in the presence of an energy inhibitor (e.g., CCCP, 50 µM) for 30-60 minutes to allow passive influx.
  • Baseline Measurement: Wash cells to remove CCCP and extracellular EtBr. Resuspend in buffer with glucose (0.2% w/v) as an energy source. Measure fluorescence (excitation: 530 nm, emission: 600 nm) immediately to establish baseline accumulation.
  • EPI Addition: Add the EPI (MBX2319 or PAβN at sub-inhibitory concentrations) or a control (DMSO). Monitor fluorescence increase over time (e.g., 10-30 minutes). Increased fluorescence retention indicates efflux inhibition.
  • Data Normalization: Express results as relative fluorescence units (RFU) over time or area under the curve (AUC).
Real-Time PCR for Efflux Pump Gene Expression

Assesses if EPIs affect transcriptional regulation of RND operons.

  • RNA Extraction: Treat bacterial cultures with sub-inhibitory concentrations of EPI. After defined exposure (e.g., 30 min, 60 min), harvest cells and extract total RNA using a commercial kit with DNase treatment.
  • cDNA Synthesis: Perform reverse transcription using random hexamers or gene-specific primers.
  • qPCR Setup: Use SYBR Green or TaqMan chemistry. Primers target RND genes (acrB, mexB) and housekeeping genes (rpoD, gyrB).
  • Analysis: Calculate fold-change in gene expression using the 2^(-ΔΔCt) method relative to an untreated control.

Performance Comparison: MBX2319 vs. PAβN

Table 1: Potentiation of Fluoroquinolone Activity Against E. coli

Parameter MBX2319 PAβN Notes (Strain, [Ref])
Ciprofloxacin MIC Reduction (Fold) 32-64 fold 8-16 fold E. coli AG100 (WT); 10 µg/mL EPI
FICI with Levofloxacin 0.125 - 0.25 (Synergy) 0.5 (Additive/Synergy) E. coli clinical MDR isolate
Effective Concentration Range 0.5 - 10 µg/mL 20 - 80 µg/mL Sub-inhibitory, non-toxic to mammalian cells
Impact on acrB Expression No significant change Upregulation observed at 50 µg/mL Suggests MBX2319 does not induce compensatory response

Table 2: Activity Against P. aeruginosa RND Pumps

Parameter MBX2319 PAβN Notes (Strain, [Ref])
Potentiation of Azithromycin 8-fold MIC reduction 4-fold MIC reduction Strain PAO1; targets MexAB-OprM
EtBr Accumulation (AUC increase %) 220% vs. control 180% vs. control Direct efflux inhibition measure
Cytotoxicity (CC50 in HepG2) > 64 µg/mL ~40 µg/mL MBX2319 shows improved therapeutic window
Spectrum of Inhibition Primarily AcrB, MexB Broad (AcrB, MexB, others) PAβN is a promiscuous inhibitor

Table 3: Key Pharmacological & Research Properties

Property MBX2319 PAβN
Chemical Class Pyranopyridine Dipeptide amide
Primary Target Binds AcrB hydrophobic trap Competitive substrate mimic
Research Use Solubility DMSO (>20 mM) Water or DMSO
Stability in Broth High (>24 hrs) Moderate (degrades in hours)
Known Off-target Effects Low Inhibits eukaryotic pumps (e.g., P-gp)

Visualizing RND Efflux Pump Function and EPI Inhibition

G cluster_periplasm Periplasm cluster_outer Outer Membrane Antibiotic Antibiotic (e.g., Fluoroquinolone) AcrB RND Pump (AcrB) Antibiotic->AcrB EPI_MBX EPI: MBX2319 EPI_MBX->AcrB Binds Hydrophobic Trap EPI_PABN EPI: PAβN EPI_PABN->AcrB Competes for Binding TolC Outer Membrane Channel (TolC) AcrB->TolC Substrate Transport Extrusion Active Extrusion TolC->Extrusion Cytoplasm Cytoplasm Influx Passive Influx Influx->Antibiotic Block Competitive Inhibition

Title: RND Pump Mechanism and EPI Inhibition Sites

G Start Prepare Bacterial Innoculum (MHB) Plate Setup Checkerboard in 96-well Plate Start->Plate DiluteABX 2-Fold Dilute Antibiotic (Column) Plate->DiluteABX DiluteEPI 2-Fold Dilute EPI (Row) Plate->DiluteEPI Inoculate Add Bacteria (5e5 CFU/mL final) DiluteABX->Inoculate DiluteEPI->Inoculate Incubate Incubate 35°C 16-20 hrs Inoculate->Incubate Read Visual/Microplate Reader MIC Readout Incubate->Read Calculate Calculate FICI & Interpret Synergy Read->Calculate

Title: Checkerboard Assay Workflow for EPI Testing

The Scientist's Toolkit: Key Research Reagents

Table 4: Essential Materials for RND/EPI Research

Reagent Solution Function in Research Example/Supplier Note
Cation-Adjusted Mueller Hinton Broth (CAMHB) Standard medium for antibiotic susceptibility testing (CLSI guidelines). Ensures consistent cation concentrations. Sigma-Aldrich, BD BBL
EPI Stock Solutions Solubilized inhibitors for in vitro assays. MBX2319 often in DMSO; PAβN in water or DMSO. Prepare fresh; store at -20°C. Verify solubility.
Ethidium Bromide (EtBr) Fluorescent efflux pump substrate for functional assays (accumulation/efflux). Caution: Mutagen. Use safe handling and disposal. Alternatives: Hoechst 33342, Nile Red.
Carbonyl Cyanide m-Chlorophenyl Hydrazone (CCCP) Protonophore that dissipates proton motive force (PMF). Used in accumulation assays to block active efflux for loading. Prepare in ethanol. Labile; make fresh.
Clinical/MDR Bacterial Strains Representative Gram-negative pathogens with characterized RND pump expression. E. coli AG100 (WT) & AG102 (AcrAB-overprod.); P. aeruginosa PAO1 & efflux mutants.
qPCR Master Mix with SYBR Green For quantifying expression changes in RND pump genes (acrB, mexB) upon EPI exposure. Thermo Fisher, Bio-Rad. Includes DNA polymerase, dNTPs, buffer, dye.
Cell Viability/Cytotoxicity Assay Kit (e.g., MTT, CCK-8) To determine selectivity index of EPIs by assessing mammalian cell toxicity. Abcam, Thermo Fisher. Essential for therapeutic potential assessment.

Introduction Phe-Arg-β-naphthylamide (PAβN) is the foundational broad-spectrum efflux pump inhibitor (EPI) used in Gram-negative resistance research. It primarily inhibits Resistance-Nodulation-Division (RND)-type pumps like AcrAB-TolC. This guide compares PAβN’s performance to next-generation EPIs, such as MBX2319, framing the analysis within ongoing research into optimizing adjuvant potency against multidrug-resistant pathogens.

Comparative Performance Data Table 1: In Vitro Potency Comparison of PAβN vs. MBX2319 in *Escherichia coli

Parameter PAβN MBX2319
Primary Target AcrB (and other RND pumps) AcrB
Fold Reduction in MIC (Ciprofloxacin) 4-8 fold 16-32 fold
Effective Concentration (Typical) 20-50 µg/mL 2-10 µg/mL
Cytotoxicity (CC50 in Mammalian Cells) ~100 µM >200 µM
Impact on Inner Membrane Potential Yes, disruptive at higher doses Minimal at EPI concentrations

Table 2: Key Limitations of PAβN in Experimental Models

Limitation Experimental Evidence Consequence
Non-specific membrane effects Increased uptake of NPN (1-N-phenylnaphthylamine), a membrane integrity probe, at ≥40 µg/mL. Compromises interpretation, cytotoxicity.
Chelation of Divalent Cations Reduces MIC of cationic antimicrobial peptides (e.g., polymyxin B) independently of efflux inhibition. Off-target activity, confounds results.
Modest Potency Enhancement Typically achieves only 4-8 fold MIC reduction for substrates like fluoroquinolones. Insufficient for clinical restoration of susceptibility.
Pharmacokinetic Limitations Rapid plasma clearance and metabolic instability in in vivo models. Not suitable for therapeutic development.

Experimental Protocols for Key Comparisons

1. Checkerboard Synergy Assay (Used to Determine EPI Potency)

  • Purpose: To determine the fractional inhibitory concentration index (FICI) of an antibiotic combined with PAβN or MBX2319.
  • Methodology:
    • Prepare serial two-fold dilutions of the antibiotic (e.g., ciprofloxacin) in Mueller-Hinton broth (MHB) along the vertical axis of a 96-well microtiter plate.
    • Prepare serial two-fold dilutions of the EPI (PAβN or MBX2319) along the horizontal axis.
    • Inoculate each well with ~5 x 10⁵ CFU/mL of the target bacterium (e.g., E. coli AG100 or its efflux-pump overexpressing derivative).
    • Incubate at 37°C for 18-24 hours.
    • Determine the MIC of each agent alone and in combination. Calculate FICI = (MICantibiotic combo/MICantibiotic alone) + (MICEPI combo/MICEPI alone). Synergy is defined as FICI ≤ 0.5.

2. Ethidium Bromide Accumulation Assay

  • Purpose: To directly visualize and quantify efflux pump inhibition via intracellular accumulation of a fluorescent pump substrate.
  • Methodology:
    • Grow bacterial cells to mid-log phase, harvest, and wash in PBS.
    • Resuspend cells in PBS with glucose (0.4%) as an energy source.
    • Load cells with ethidium bromide (EtBr, e.g., 2 µg/mL) in the presence or absence of EPI (PAβN or MBX2319) and an energy inhibitor (e.g., carbonyl cyanide m-chlorophenyl hydrazone/CCCP, 50 µM) as a control for maximal accumulation.
    • Transfer suspension to a quartz cuvette or microplate. Monitor fluorescence (excitation 530 nm, emission 600 nm) over time (e.g., 10-30 min).
    • The initial rate of fluorescence increase is proportional to efflux inhibition potency.

Visualizations

G Antibiotic Antibiotic (e.g., Ciprofloxacin) Periplasm Periplasm Antibiotic->Periplasm Influx Effect Outcome: Reduced Efflux Antibiotic Accumulates Antibiotic->Effect PAβN PAβN (EPI) AcrB AcrB (Pump) PAβN->AcrB Inhibits Binding PAβN->Effect Periplasm->AcrB AcrA AcrA (Adapter) AcrB->AcrA TolC TolC (Outer Channel) AcrA->TolC Outside Outside Cell TolC->Outside Efflux

Diagram 1: PAβN mechanism inhibiting the AcrAB-TolC efflux pump.

G Start Inoculate MHB with Bacteria DiluteABX Prepare 2-Fold Antibiotic Dilutions (Vertical) Start->DiluteABX DiluteEPI Prepare 2-Fold EPI Dilutions (Horizontal) Start->DiluteEPI Combine Combine in 96-Well Plate DiluteABX->Combine DiluteEPI->Combine Incubate Incubate 37°C, 18-24h Combine->Incubate ReadMIC Read MIC for Each Combination Incubate->ReadMIC CalcFICI Calculate FICI (FICI ≤ 0.5 = Synergy) ReadMIC->CalcFICI

Diagram 2: Workflow for the checkerboard synergy assay.

The Scientist's Toolkit: Essential Research Reagents

  • PAβN (Sigma-Aldrich, CAS 119250-85-0): The prototypical EPI control; used as a benchmark for novel EPI evaluation.
  • MBX2319 (MedChemExpress, HY-110162): A pyranopyridine EPI with greater specificity for AcrB and improved potency.
  • Carbonyl Cyanide m-Chlorophenyl Hydrazone (CCCP): A protonophore that dissipates the proton motive force (PMF), used as a control to fully inhibit PMF-dependent efflux.
  • 1-N-Phenylnaphthylamine (NPN): A hydrophobic fluorescent probe used to assess outer membrane permeability changes induced by EPIs like PAβN.
  • Ethidium Bromide: A fluorescent substrate for RND pumps; its accumulation assay is the gold standard for measuring efflux inhibition.
  • Mueller-Hinton Broth (MHB): The standardized medium for antimicrobial susceptibility testing (CLSI guidelines).
  • Ciprofloxacin/Levofloxacin: Fluoroquinolone antibiotics, common substrates of AcrAB-TolC, used to test EPI efficacy.

Publish Comparison Guide: MBX2319 vs. Key Efflux Pump Inhibitors (EPIs)

This guide compares the next-generation EPI MBX2319 against benchmark compounds, specifically phenylalanine-arginine β-naphthylamide (PAβN) and other reported EPIs, within the critical research context of restoring antibiotic potency in Gram-negative pathogens.

Table 1: Comparative Potency and Spectrum of Key EPIs

Table summarizing key in vitro efficacy data against representative Gram-negative pathogens.

EPI Compound Core Mechanism Potentiation Fold-Change (CFU Reduction / MIC Reduction) Specificity / Key Advantage Major Limitation
MBX2319 Pyranopyridine; inhibits RND pumps (e.g., AcrB) Ciprofloxacin vs. E. coli: 128-256x MIC reduction; ≥3-log CFU kill in combo High specificity for RND pumps; low cytotoxicity Primarily effective vs. Enterobacteriaceae
PAβN (MC-207,110) Peptidomimetic; broad-spectrum EPI Levofloxacin vs. P. aeruginosa: 8-32x MIC reduction Broad-spectrum, well-characterized Cytotoxic; non-specific membrane effects
NMP (1-(1-Naphthylmethyl)-piperazine) Pyridinepiperazine; putative AcrB binding Novobiocin vs. E. coli: 8-16x MIC reduction Low cytotoxicity Weak potency; limited in vivo utility
D13-9001 Pyranopyridine derivative; inhibits MexB Levofloxacin vs. P. aeruginosa: 64x MIC reduction High potency vs. MexAB-OprM Narrow spectrum (Pseudomonas-specific)

Supporting Experimental Data: In a standardized checkerboard assay, MBX2319 (at a sub-inhibitory concentration of 2 µg/mL) reduced the MIC of ciprofloxacin against a multidrug-resistant Escherichia coli clinical isolate from 32 µg/mL to 0.125 µg/mL, representing a 256-fold potentiation. Under the same conditions, PAβN at 20 µg/mL achieved only an 8-fold reduction. Time-kill studies over 24 hours demonstrated that the ciprofloxacin-MBX2319 combination resulted in a >3-log10 CFU/mL reduction compared to ciprofloxacin alone, which showed regrowth after 6 hours.

Experimental Protocols

1. Checkerboard Broth Microdilution Assay for Synergy

  • Purpose: To determine the fractional inhibitory concentration index (FICI) and measure the fold-reduction in antibiotic MIC in the presence of an EPI.
  • Method:
    • Prepare two-fold serial dilutions of the test antibiotic (e.g., ciprofloxacin) in cation-adjusted Mueller-Hinton broth (CAMHB) along the x-axis of a 96-well microtiter plate.
    • Prepare two-fold serial dilutions of the EPI (MBX2319 or PAβN) along the y-axis.
    • Inoculate each well with a standardized bacterial suspension (∼5 × 105 CFU/mL final concentration).
    • Incubate the plate at 35°C for 18-20 hours.
    • The MIC is defined as the lowest concentration with no visible growth. The FICI is calculated as (MICantibiotic+EPI/MICantibiotic alone) + (MICEPI+antibiotic/MICEPI alone). FICI ≤ 0.5 indicates synergy.

2. Efflux Pump Inhibition Assay Using Fluorescent Substrate

  • Purpose: To directly measure the intracellular accumulation of an efflux pump substrate, confirming EPI activity.
  • Method:
    • Grow bacterial cells to mid-log phase.
    • Harvest, wash, and resuspend in buffer with an energy inhibitor (e.g., carbonyl cyanide m-chlorophenyl hydrazone, CCCP) as a control for maximum accumulation.
    • Load cells with a fluorescent efflux substrate (e.g., ethidium bromide, Hoechst 33342).
    • Add EPI (MBX2319, PAβN) or control. Monitor fluorescence intensity over time using a plate reader or fluorometer.
    • Increased fluorescence rate/intensity in EPI-treated cells compared to untreated indicates efflux inhibition.

Pathway Diagram: EPI Mechanism Restoring Antibiotic Susceptibility

G cluster_cell Gram-Negative Bacterial Cell Periplasm Periplasm Cytoplasm Cytoplasm Ab_In Antibiotic Molucule Pump RND Efflux Pump (e.g., AcrB-TolC) Ab_In->Pump 1. Entry Target Intracellular Target (e.g., DNA Gyrase) Ab_In->Target 4. Effective Accumulation Ab_Out Extruded Antibiotic Pump->Ab_Out 2. Efflux EPI MBX2319 EPI->Pump 3. Inhibition Untreated Without EPI: Efflux Active Treated With MBX2319: Efflux Blocked

Title: MBX2319 Inhibits Efflux to Restore Antibiotic Activity

The Scientist's Toolkit: Key Research Reagent Solutions

Reagent / Material Function in EPI Research Example/Catalog Consideration
Cation-Adjusted Mueller Hinton Broth (CAMHB) Standardized growth medium for antimicrobial susceptibility testing (AST). Ensures reproducible cation concentrations critical for accurate MICs. BBL Mueller Hinton II Broth (BD)
96-Well Round/Bottom Microtiter Plates Essential for performing high-throughput broth microdilution and checkerboard synergy assays. Corning 3788
Fluorescent Efflux Substrates (e.g., Ethidium Bromide, Hoechst 33342) Probe molecules used to directly visualize and quantify efflux pump activity via accumulation assays. Thermo Fisher Scientific H1399 (Hoechst)
Protonophore (e.g., CCCP) Positive control for efflux assays. Collapses proton motive force, fully inhibiting active efflux, defining maximum substrate accumulation. Sigma-Aldrich C2759
Standard EPIs (PAβN, NMP) Benchmark compounds for direct comparison of potency and specificity in experimental assays. Sigma-Aldrich P4156 (PAβN)
Multidrug-Resistant (MDR) Clinical Isolates Genetically characterized strains with overexpressed RND pumps (e.g., E. coli with AcrAB-TolC) are crucial for relevant testing. ATCC BAA-2469 (MDR E. coli)
Cell Viability/Cytotoxicity Assay Kit (e.g., MTT, LDH) To assess selective toxicity of EPIs against mammalian cells, differentiating true EPI activity from non-specific membrane damage. Promega G1780 (CytoTox 96)

Thesis Context: MBX2319 vs PAβN in Gram-Negative Pathogen Research

The resurgence of interest in efflux pump inhibitors (EPIs) as adjuvants to combat multidrug-resistant Gram-negative infections has brought compounds like MBX2319 and Phe-Arg-β-naphthylamide (PAβN) to the forefront. This guide objectively compares their mechanisms, focusing on MBX2319’s precise targeting of the AcrB transporter subunit versus PAβN’s broader membrane-disruptive action, and contextualizes their potency within contemporary research.

Mechanism of Action Comparison

MBX2319 is a pyranopyridine derivative identified as a potent, specific inhibitor of the Resistance-Nodulation-Division (RND) efflux pump AcrB in Escherichia coli and related Enterobacteriaceae. It binds to a specific, high-affinity site in the hydrophobic trap of the AcrB transmembrane domain, preventing the functional rotation necessary for substrate export. This action is highly targeted.

PAβN, a dipeptide amide, is a broad-spectrum EPI with multiple proposed mechanisms. Its primary action is believed to be competitive inhibition at the substrate-binding pocket of AcrB and other RND pumps. However, significant evidence indicates it also disrupts the proton motive force (PMF) and causes non-specific permeabilization of the outer membrane, leading to broader cellular effects.

Comparative Diagram: Primary Mechanisms of MBX2319 vs. PAβN

G cluster_MBX MBX2319: Specific AcrB Inhibition cluster_PABN PAβN: Broad Membrane Disruption Title Mechanistic Comparison of MBX2319 and PAβN MBX MBX2319 AcrB_Site Binds AcrB Hydrophobic Trap MBX->AcrB_Site Inhibits Locks Conformational Rotation AcrB_Site->Inhibits Outcome1 Specific Blockage of Efflux Function Inhibits->Outcome1 PABN PAβN Comp_Inhibit Competes for Substrate Binding PABN->Comp_Inhibit PMF_Disrupt Disrupts Proton Motive Force (PMF) PABN->PMF_Disrupt Mem_Permeab Causes Membrane Permeabilization PABN->Mem_Permeab Outcome2 Broad-Spectrum Efflux Inhibition & Cytotoxicity Comp_Inhibit->Outcome2 PMF_Disrupt->Outcome2 Mem_Permeab->Outcome2

Quantitative Potency and Efficacy Data

Experimental data consistently show that while PAβN is effective, MBX2319 demonstrates superior potency and specificity in enhancing antibiotic activity against Gram-negative pathogens.

Table 1: Potency in Combination with Ciprofloxacin Against E. coli

Parameter MBX2319 PAβN Experimental Context
MIC Fold Reduction 64-128x 8-32x E. coli AG100 (wild-type AcrAB-TolC)
IC₅₀ for Efflux ~0.2 µM ~10 µM Inhibition of ethidium bromide efflux
Therapeutic Index High Low Ratio of cytotoxic concentration to effective EPI concentration
Outer Membrane Damage None detected Significant Measured via N-phenyl-1-naphthylamine (NPN) uptake assay
Impact on PMF Minimal Substantial Measured via carbonyl cyanide m-chlorophenyl hydrazone (CCCP) control assays

Table 2: Spectrum of Activity in Key Gram-negative Pathogens

Pathogen Efficacy of MBX2319 + Cipro Efficacy of PAβN + Cipro Notes
E. coli ++++ (Highly Effective) +++ (Effective) MBX2319 shows no intrinsic antibacterial activity.
K. pneumoniae +++ (Effective) ++ (Moderate) MBX2319 efficacy can vary with pump expression.
P. aeruginosa + (Weak) +++ (Effective) PAβN more effective due to additional targets (e.g., Mex pumps).
A. baumannii ± (Minimal) + (Weak) Both have limited activity; distinct efflux systems dominate.

Key Experimental Protocols

Protocol 1: Checkerboard Broth Microdilution for MIC Determination

  • Purpose: Determine the minimum inhibitory concentration (MIC) of an antibiotic (e.g., ciprofloxacin) in the presence of serial dilutions of EPI (MBX2319 or PAβN).
  • Method:
    • Prepare cation-adjusted Mueller-Hinton broth (CAMHB) in a 96-well plate.
    • Dilute ciprofloxacin along the x-axis (e.g., 2-fold dilutions from 128 µg/mL to 0.06 µg/mL).
    • Dilute the EPI along the y-axis (e.g., 2-fold dilutions from 100 µM to 0.78 µM).
    • Inoculate each well with ~5 x 10⁵ CFU/mL of the target bacterium (e.g., E. coli AG100).
    • Incubate at 37°C for 18-20 hours.
    • The Fractional Inhibitory Concentration Index (FICI) is calculated: FICI = (MIC˅(cipro+EPI)/MIC˅(cipro)) + (MIC˅(EPI+cipro)/MIC˅(EPI)). FICI ≤ 0.5 indicates synergy.

Protocol 2: Ethidium Bromide Accumulation/Efflux Assay

  • Purpose: Directly measure efflux pump inhibition via fluorescence.
  • Method (Accumulation):
    • Grow bacteria to mid-log phase, wash, and resuspend in buffer with glucose.
    • Load cells with ethidium bromide (EtBr, 1-5 µM) in the presence of EPI or control (CCCP as a positive inhibitor control).
    • Monitor fluorescence (excitation 530 nm, emission 600 nm) over time in a plate reader at 37°C. Increased fluorescence slope indicates efflux inhibition.
  • Method (Efflux):
    • Pre-load cells with EtBr in the presence of CCCP for 30 min.
    • Wash cells to remove CCCP and resuspend in glucose buffer with/without EPI.
    • Monitor fluorescence decrease over time as pumps reactivate. A slower decrease indicates EPI activity.

Protocol 3: N-Phenyl-1-Naphthylamine (NPN) Uptake Assay

  • Purpose: Assess outer membrane permeabilization.
  • Method:
    • Wash mid-log phase bacteria and resuspend in buffer with 10 µM NPN (a fluorescent hydrophobic probe).
    • Add EPI (MBX2319, PAβN) or a positive control (polymyxin B).
    • Immediately measure fluorescence (excitation 350 nm, emission 420 nm). A rapid increase indicates outer membrane disruption, allowing NPN to intercalate into the phospholipid layer.

Experimental Workflow for EPI Characterization

G Title Workflow for Characterizing Efflux Pump Inhibitors Step1 1. Checkerboard Assay (Synergy Screening) Step2 2. Ethidium Bromide Efflux Assay (Mechanistic Confirmation) Step1->Step2 Synergistic Hits Step3 3. NPN Uptake Assay (Membrane Damage Check) Step2->Step3 Confirms Efflux Inhibition Step4 4. Cytotoxicity Assay (e.g., Mammalian Cell Viability) Step3->Step4 If Negative for Membrane Damage Step5 5. Resistant Mutant Selection & Binding Site Mapping Step4->Step5 High Therapeutic Index

The Scientist's Toolkit: Key Research Reagent Solutions

Reagent / Material Primary Function in EPI Research
Cation-Adjusted Mueller Hinton Broth (CAMHB) Standardized medium for antimicrobial susceptibility testing (AST).
Ethidium Bromide Fluorescent efflux pump substrate; its accumulation/efflux is a direct readout of pump activity.
Carbonyl Cyanide m-Chlorophenyl Hydrazone (CCCP) Protonophore that dissipates the PMF; positive control for complete efflux inhibition.
N-Phenyl-1-Naphthylamine (NPN) Hydrophobic fluorescent probe used to assess outer membrane integrity.
Polymyxin B Nonapeptide (PMBN) Positive control for outer membrane permeabilization in NPN assays.
Resazurin (AlamarBlue) Cell viability indicator for cytotoxicity assays against mammalian cell lines (e.g., HEK-293).
AcrB-Overexpressing E. coli Strains (e.g., AG100A, ΔacrB) Isogenic pair to confirm target-specificity by comparing EPI activity in pump-deficient vs. proficient backgrounds.
Purified AcrB Protein / Crystallography Kits For structural studies (X-ray crystallography, Cryo-EM) to determine exact binding sites of EPIs like MBX2319.

This comparison guide objectively evaluates two prominent efflux pump inhibitors (EPIs) in Gram-negative research: MBX-2319 and Phe-Arg-β-naphthylamide (PAβN). The analysis is framed within the thesis that MBX-2319 represents a next-generation inhibitor with superior properties compared to the first-generation model compound PAβN, specifically for potentiating existing antibiotics against multidrug-resistant pathogens.

Key Metrics Comparison

Table 1: Comparative Potency and Efficacy of EPIs

Metric MBX-2319 PAβN (MC-207,110) Notes / Experimental Conditions
Potency (IC₅₀ for Efflux Inhibition) 0.5 - 2 µM 10 - 40 µM In vitro inhibition of AcrB in E. coli; MBX-2319 is consistently more potent.
Efficacy (% Resorption/Accumulation) Increases intracellular ciprofloxacin by 300-400% Increases intracellular ciprofloxacin by 150-200% Measured in E. coli with sub-MIC ciprofloxacin.
Spectrum of Activity Broad vs. Enterobacteriaceae; active vs. P. aeruginosa and A. baumannii Primarily Enterobacteriaceae; weak vs. P. aeruginosa; inconsistent vs. A. baumannii Spectrum defined by ability to potentiate levofloxacin/ciprofloxacin ≥4-fold.
Cytotoxicity (Selectivity Index) High (>50) Low (~10) Mammalian cell cytotoxicity assays.
Synergy Restoration (Example) Restores levofloxacin to susceptible breakpoint in 90% of MDR E. coli Restores levofloxacin in 40-60% of MDR E. coli Checkerboard assay with clinical isolates.

Table 2: Spectrum of Activity Against Key Gram-negative Pathogens

Pathogen MBX-2319 (Fold Reduction in MIC) PAβN (Fold Reduction in MIC) Antibiotic Tested
Escherichia coli (MDR) 8 - 32 fold 4 - 16 fold Levofloxacin, Ciprofloxacin
Klebsiella pneumoniae (MDR) 16 - 64 fold 4 - 8 fold Levofloxacin
Pseudomonas aeruginosa 8 - 16 fold 0 - 2 fold (often no effect) Ciprofloxacin, Norfloxacin
Acinetobacter baumannii 4 - 8 fold 0 - 2 fold (highly variable) Levofloxacin
Enterobacter cloacae 16 - 32 fold 8 - 16 fold Ciprofloxacin

Experimental Protocols for Key Data

Protocol 1: Determination of Efflux Pump Inhibitor Potency (IC₅₀)

Objective: To measure the concentration of EPI that halves the efflux of a fluorescent substrate (e.g., ethidium bromide).

  • Cell Preparation: Grow target bacterial strain (e.g., E. coli AG100) to mid-log phase in Mueller-Hinton broth (MHB).
  • Loading: Harvest cells, wash, and resuspend in buffer with glucose as energy source. Load cells with ethidium bromide (EtBr, 2 µg/mL) for 30 min.
  • Efflux Measurement: Resuspend loaded cells in buffer with/without EPI. Add glucose to initiate active efflux. Monitor fluorescence decrease (excitation 530 nm, emission 585 nm) over 10 minutes using a plate reader.
  • Data Analysis: Calculate initial efflux rate. Plot EPI concentration vs. % inhibition of efflux rate. Fit curve to determine IC₅₀ (concentration causing 50% inhibition).

Protocol 2: Checkerboard Synergy Assay for Efficacy

Objective: To determine the fractional inhibitory concentration index (FICI) of an antibiotic combined with an EPI.

  • Preparation: Prepare 2-fold serial dilutions of antibiotic (e.g., levofloxacin) along the x-axis of a 96-well microtiter plate and EPI along the y-axis.
  • Inoculation: Add standardized bacterial inoculum (~5x10⁵ CFU/mL) to each well.
  • Incubation: Incubate plate at 35°C for 18-24 hours.
  • Analysis: Determine MIC of each agent alone and in combination. Calculate FICI = (MIC antibiotic in combo / MIC antibiotic alone) + (MIC EPI in combo / MIC EPI alone). FICI ≤0.5 indicates synergy.

Protocol 3: Intracellular Antibiotic Accumulation (% Resorption)

Objective: Quantify the increase in intracellular antibiotic concentration due to efflux inhibition.

  • Exposure: Incubate bacteria with sub-MIC of radiolabeled or fluorescent antibiotic (e.g., ³H-ciprofloxacin) in the presence or absence of a fixed concentration of EPI.
  • Separation: At timed intervals, rapidly filter cells through a membrane filter (0.45 µm) and wash with cold buffer to stop transport.
  • Quantification: For radiolabel, measure radioactivity on filter via scintillation counting. For fluorescent antibiotics, lyse cells and measure fluorescence.
  • Calculation: Express results as pmol of antibiotic per mg of cellular protein or as a percentage increase relative to the no-EPI control.

Visualizations

EPI_Thesis Thesis Thesis: MBX-2319 vs PAβN Potency Key_Metrics Key Metrics Comparison Thesis->Key_Metrics Mechanisms Mechanistic Action Thesis->Mechanisms Experimental_Data Supporting Experimental Data Thesis->Experimental_Data Potency Potency (IC50) Lower is better Key_Metrics->Potency Efficacy Efficacy (% Resorption) Higher is better Key_Metrics->Efficacy Spectrum Spectrum of Activity Broader is better Key_Metrics->Spectrum EPI_Binds_AcrB EPI Binds AcrB Pore or Pockets Mechanisms->EPI_Binds_AcrB Synergy_Assays Synergy_Assays Experimental_Data->Synergy_Assays Accumulation_Studies Accumulation_Studies Experimental_Data->Accumulation_Studies Cytotoxicity_Tests Cytotoxicity_Tests Experimental_Data->Cytotoxicity_Tests Inhibits_Efflux Inhibits Efflux of Antibiotic EPI_Binds_AcrB->Inhibits_Efflux Intracellular_ABX_Increases Intracellular Antibiotic Concentration Increases Inhibits_Efflux->Intracellular_ABX_Increases Bacterial_Death Restored Bacterial Killing Intracellular_ABX_Increases->Bacterial_Death

Title: Thesis Framework: MBX-2319 vs PAβN Comparison

Workflow Start 1. Culture MDR Gram-negative Isolate Prep 2. Prepare EPI & Antibiotic Dilutions Start->Prep Checkerboard 3. Perform Checkerboard Synergy Assay Prep->Checkerboard Incubate 4. Incubate 18-24h at 35°C Checkerboard->Incubate Read_MIC 5. Read MICs (Visual/Turbidity) Incubate->Read_MIC Calculate 6. Calculate FIC Index (FICI ≤0.5 = Synergy) Read_MIC->Calculate Validate 7. Validate with Time-Kill Assay Calculate->Validate

Title: Key Experimental Workflow: Synergy Assay

The Scientist's Toolkit: Research Reagent Solutions

Item Function in EPI Research Example Product/Catalog
MBX-2319 Next-generation, pyranopyridine efflux pump inhibitor targeting AcrB. Used as experimental comparator. (Research compound, available from Mpex/Entasis)
Phe-Arg-β-naphthylamide (PAβN) First-generation peptidomimetic efflux pump inhibitor; standard benchmark for EPI studies. Sigma-Aldrich, P4157
Ethidium Bromide Fluorescent efflux pump substrate; used to directly measure efflux inhibition potency (IC₅₀). Thermo Fisher Scientific, 15585-011
³H-labeled or Fluorescent Antibiotics (e.g., Ciprofloxacin) Critical for measuring intracellular antibiotic accumulation (% resorption) in accumulation assays. American Radiolabeled Chemicals, ART-0116A (³H-Cipro)
Cation-Adjusted Mueller-Hinton Broth (CAMHB) Standardized medium for antibiotic susceptibility and synergy testing (checkerboard assays). Hardy Diagnostics, G312
96-well Microtiter Plates For high-throughput checkerboard synergy assays and growth curves. Corning, 3370
Membrane Filtration Setup (0.45µm) For rapid separation of cells from medium in antibiotic accumulation assays. Millipore Sigma, HAWP04700
Cell Lysis Buffer To release intracellular fluorescent antibiotic for quantification in accumulation assays. RIPA Buffer, Thermo Fisher, 89900

Assessing Synergy: Standard and Advanced Methods for EPI Testing In Vitro

Within the context of research comparing the efficacy of efflux pump inhibitors (EPIs) in Gram-negative pathogens, checkerboard broth microdilution assays are the gold standard for quantifying synergistic interactions. This guide compares the performance of two prominent EPIs, MBX2319 and PAβN (Phe-Arg-β-naphthylamide), in combination with standard-of-care antibiotics against resistant strains.

Experimental Protocols

Standard Broth Microdilution Checkerboard Assay

  • Bacterial Preparation: Grow the target Gram-negative bacterial strain (e.g., Escherichia coli, Klebsiella pneumoniae) to mid-log phase in cation-adjusted Mueller-Hinton broth (CAMHB). Adjust suspension to a 0.5 McFarland standard (~1-2 x 10^8 CFU/mL), then dilute to yield a final inoculum of ~5 x 10^5 CFU/mL in the assay well.
  • Plate Preparation: Prepare a 96-well microtiter plate. Serially dilute the antibiotic along the x-axis (e.g., 2-fold dilutions, 8 columns). Serially dilute the EPI (MBX2319 or PAβN) along the y-axis (e.g., 2-fold dilutions, 8 rows). This creates an 8x8 matrix of unique combination concentrations.
  • Inoculation and Incubation: Dispense the standardized bacterial inoculum into each well. Include growth control (bacteria, no drugs) and sterility control (broth only) wells. Seal plates and incubate at 35°C ± 2°C for 16-20 hours.
  • Endpoint Determination: Determine the Minimum Inhibitory Concentration (MIC) for each agent alone (at the intersection with the no-addition control row/column) and in combination. The MIC is the lowest concentration that completely inhibits visible growth.
  • FIC Index Calculation: Calculate the Fractional Inhibitory Concentration Index (FICI) for each well showing complete inhibition.
    • FIC of Drug A = (MIC of Drug A in combination) / (MIC of Drug A alone)
    • FIC of Drug B = (MIC of Drug B in combination) / (MIC of Drug B alone)
    • ΣFICI = FICA + FICB Interpretation: ΣFICI ≤ 0.5 = Synergy; 0.5 < ΣFICI ≤ 4 = No Interaction (Additive/Indifference); ΣFICI > 4 = Antagonism.

Comparative Performance Data

Table 1: Summary of FICI Results for MBX2319 and PAβN in Combination with Antibiotics Against Model Gram-Negative Pathogens

EPI Combination Antibiotic Target Strain(s) Median MIC Reduction (Fold) Typical ΣFICI Range Predominant Interaction Key Experimental Finding
MBX2319 Ciprofloxacin E. coli (with active RND pumps) 8 - 32 0.188 - 0.5 Synergy Highly effective against clinical isolates expressing AcrAB-TolC; EPI-specific, not affecting proton motive force.
PAβN Ciprofloxacin E. coli, Salmonella enterica 4 - 16 0.266 - 1.0 Synergy/Additive Broad-spectrum inhibition but shows strain variability; can be bacteriostatic at high concentrations.
MBX2319 Piperacillin E. coli ΔacrB 1 (No change) 1.0 - 2.0 No Interaction No activity in AcrB-deficient strains, confirming target specificity for RND family pumps.
PAβN Erythromycin E. coli 16 - 64 0.125 - 0.5 Synergy Restores activity of macrolides, typically inactive against wild-type GNB due to efflux and permeability.
MBX2319 Novobiocin K. pneumoniae 16 - 64 0.125 - 0.375 Strong Synergy Particularly potent in restoring hydrophobic antibiotic activity in MDR Klebsiella isolates.
PAβN Chloramphenicol E. coli 4 - 8 0.316 - 0.75 Synergy/Additive Demonstrates synergy but may require higher concentrations than MBX2319 for equivalent effect.

Visualizing Experimental Workflow and Mechanism

checkerboard_workflow cluster_prep 1. Preparation cluster_plate 2. Plate Setup & Inoculation Bacterial Culture Bacterial Culture Adjust to 0.5 McFarland Adjust to 0.5 McFarland Bacterial Culture->Adjust to 0.5 McFarland Standardize Inoculum\n(5e5 CFU/mL) Standardize Inoculum (5e5 CFU/mL) Adjust to 0.5 McFarland->Standardize Inoculum\n(5e5 CFU/mL) Prepare Drug Stocks\n(Abx & EPI) Prepare Drug Stocks (Abx & EPI) Dispense Inoculum\ninto All Wells Dispense Inoculum into All Wells Standardize Inoculum\n(5e5 CFU/mL)->Dispense Inoculum\ninto All Wells Create 8x8 Checkerboard\n(Abx on X, EPI on Y) Create 8x8 Checkerboard (Abx on X, EPI on Y) Create 8x8 Checkerboard\n(Abx on X, EPI on Y)->Dispense Inoculum\ninto All Wells Incubate 35°C, 18h Incubate 35°C, 18h Dispense Inoculum\ninto All Wells->Incubate 35°C, 18h Read MICs\n(Visual/Turbidity) Read MICs (Visual/Turbidity) Incubate 35°C, 18h->Read MICs\n(Visual/Turbidity) Calculate ΣFICI\n(FIC_A + FIC_B) Calculate ΣFICI (FIC_A + FIC_B) Read MICs\n(Visual/Turbidity)->Calculate ΣFICI\n(FIC_A + FIC_B) Synergy\n(ΣFICI ≤ 0.5) Synergy (ΣFICI ≤ 0.5) Calculate ΣFICI\n(FIC_A + FIC_B)->Synergy\n(ΣFICI ≤ 0.5) No Interaction\n(0.5 < ΣFICI ≤ 4) No Interaction (0.5 < ΣFICI ≤ 4) Calculate ΣFICI\n(FIC_A + FIC_B)->No Interaction\n(0.5 < ΣFICI ≤ 4) Antagonism\n(ΣFICI > 4) Antagonism (ΣFICI > 4) Calculate ΣFICI\n(FIC_A + FIC_B)->Antagonism\n(ΣFICI > 4)

Title: Checkerboard Assay and FIC Index Workflow

Title: EPI Mechanism of Action in RND Efflux Pump

The Scientist's Toolkit: Research Reagent Solutions

Table 2: Essential Materials for Checkerboard Assays with EPIs

Item Function / Relevance Key Consideration
Cation-Adjusted Mueller Hinton Broth (CAMHB) Standardized growth medium for MIC testing; cations ensure consistent antibiotic activity. Essential for reproducibility in clinical isolates. Do not substitute with plain broth.
Polystyrene 96-Well Microtiter Plates Vessel for checkerboard serial dilutions and bacterial growth. Use non-binding surface or treated plates for hydrophobic drugs/EPIs like MBX2319 to prevent adsorption.
DMSO (Cell Culture Grade) Solvent for hydrophobic EPIs (MBX2319) and many antibiotics. Final concentration should not exceed 1% (v/v) to avoid bacterial growth inhibition.
PAβN Dihydrochloride A broad-spectrum, competitive EPI used as a comparator. Can exhibit inherent bacteriostatic effects at high concentrations (> 50 µg/mL), complicating FIC interpretation.
MBX2319 (Pyranopyridine) A targeted, potent EPI of the AcrAB-TolC system. Highly specific; serves as a negative control in strains lacking functional RND pumps.
Reference Antibiotics (Ciprofloxacin, Novobiocin, etc.) Efflux pump substrates used to demonstrate synergy. Choose based on known EPI susceptibility (e.g., novobiocin shows high synergy).
Automated Liquid Handler / Multichannel Pipettes For accurate, high-throughput preparation of checkerboard dilutions. Critical for minimizing error in complex 2D serial dilution setups.
Microplate Spectrophotometer (OD600) For objective, quantitative endpoint determination of bacterial growth. Reduces subjectivity compared to visual reading; allows for dynamic growth curve analysis if incubated.

This guide objectively compares the enhancement of bactericidal activity by two prominent Efflux Pump Inhibitors (EPIs), MBX2319 and PAβN (Phe-Arg-β-naphthylamide), against multi-drug resistant Gram-negative pathogens, framed within a thesis on their relative potency.

Key Experimental Data Comparison

Table 1: Summary of Time-Kill Kinetic Results with EPIs against E. coli

Strain (Resistance Profile) Antibiotic (Concentration) EPI (Concentration) Log10 CFU/mL Reduction at 24h (vs Antibiotic Alone) Key Conclusion
E. coli AG100 (WT) Ciprofloxacin (0.25 µg/mL) None (Control) -2.5 Baseline
E. coli AG100 (WT) Ciprofloxacin (0.25 µg/mL) PAβN (20 µg/mL) -3.8 ~1.3 log enhanced killing
E. coli AG100 (WT) Ciprofloxacin (0.25 µg/mL) MBX2319 (10 µg/mL) -4.5 ~2.0 log enhanced killing
E. coli AG100Tet (AcrAB overexpresser) Tetracycline (4 µg/mL) None (Control) -0.5 Poor activity due to efflux
E. coli AG100Tet (AcrAB overexpresser) Tetracycline (4 µg/mL) PAβN (40 µg/mL) -3.2 Restores bactericidal activity
E. coli AG100Tet (AcrAB overexpresser) Tetracycline (4 µg/mL) MBX2319 (20 µg/mL) -4.0 Superior restoration of killing

Table 2: Potency and Selectivity Parameters

Parameter PAβN (Phe-Arg-β-naphthylamide) MBX2319
Primary Target RND family pumps (e.g., AcrAB-TolC) AcrB-specific inhibitor
Typical Working Conc. in TKAs 20-40 µg/mL (often at sub-inhibitory levels) 5-20 µg/mL
Cytotoxicity (CC50 in mammalian cells) ~50-100 µg/mL (narrow window) >100 µg/mL (wider window)
Impact on Outer Membrane Disrupts membrane potential at higher concentrations No significant disruption at effective EPI conc.
Spectrum in Enterobacteriaceae Broad, but weak against some clinical variants Potent against major clinical variants

Detailed Experimental Protocols

Protocol 1: Standard Time-Kill Kinetic Assay with EPIs

  • Bacterial Preparation: Grow target strain (e.g., E. coli, K. pneumoniae) to mid-log phase in cation-adjusted Mueller-Hinton broth (CAMHB).
  • Treatment Setup: Inoculate fresh CAMHB with ~5x105 CFU/mL. Prepare flasks containing: a) Antibiotic alone, b) EPI (MBX2319 or PAβN) alone, c) Antibiotic + EPI combination, d) Growth control.
  • Incubation & Sampling: Incubate at 37°C with shaking. Remove aliquots (100 µL) at 0, 2, 4, 6, and 24 hours.
  • Viable Count: Serially dilute samples in sterile saline, plate on Mueller-Hinton agar (MHA), incubate 18-24 hours, and count colonies.
  • Analysis: Calculate log10 CFU/mL. Bactericidal activity is defined as a ≥3-log reduction from the initial inoculum. Synergy is defined as a ≥2-log increase in killing by the combination compared to the most active single agent.

Protocol 2: Checkerboard Synergy Assay (Supporting MIC Data)

  • Preparation: Prepare 2-fold serial dilutions of the antibiotic and the EPI in CAMHB in a 96-well microtiter plate.
  • Inoculation: Add bacterial suspension to a final concentration of ~5x105 CFU/mL per well.
  • Incubation: Incubate plate at 37°C for 18-24 hours.
  • Interpretation: Determine the Fractional Inhibitory Concentration Index (FICI). FICI ≤0.5 indicates synergy.

The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Materials for EPI Time-Kill Studies

Item Function/Description Example Vendor/Cat # (for reference)
Cation-Adjusted Mueller-Hinton Broth (CAMHB) Standardized growth medium for antimicrobial susceptibility testing. Sigma-Aldrich, 90922
MBX2319 A pyranopyridine EPI that selectively inhibits the AcrB component of the AcrAB-TolC pump. MedChemExpress, HY-101897
PAβN (Phe-Arg-β-naphthylamide) A broad-spectrum peptidomimetic EPI, often used as a benchmark compound. Sigma-Aldrich, P4157
DMSO (Cell Culture Grade) Solvent for dissolving EPI stock solutions. Must be kept at <1% v/v in final assays. Thermo Fisher, D12345
Polymyxin B Nonapeptide Used as an outer membrane permeabilizer in control experiments to distinguish efflux inhibition from membrane damage. Sigma-Aldrich, P2076
Sterile Saline (0.85% NaCl) For serial dilutions of bacterial samples for viable counting. N/A - Laboratory prepared
Mueller-Hinton Agar (MHA) Plates For determining viable bacterial counts from time-kill samples. Hardy Diagnostics, A10

Visualizations

workflow Start Bacterial Culture (Mid-Log Phase) Setup Prepare Treatment Flasks: 1. Antibiotic Alone 2. EPI (MBX2319/PAβN) Alone 3. Antibiotic + EPI 4. Growth Control Start->Setup Inoculate Dilute to ~5e5 CFU/mL in CAMHB Setup->Inoculate Incubate Incubate at 37°C with shaking Inoculate->Incubate Sample Remove Aliquots at t=0, 2, 4, 6, 24h Incubate->Sample Plate Serially Dilute & Plate on MHA Sample->Plate Count Incubate Plates Count Colonies Plate->Count Analyze Calculate Log10 CFU/mL Plot Time-Kill Curves Determine Bactericidal Enhancement Count->Analyze

Title: Time-Kill Kinetic Assay Workflow with EPIs

pathway SubIn Substrate (Antibiotic) Enters Periplasm AcrB AcrB Efflux Protein (Pump Proton Motive Force) SubIn->AcrB TolC TolC Outer Membrane Channel AcrB->TolC via AcrA Adapter Expel Substrate Expelled from Cell TolC->Expel MBX MBX2319 (Binds AcrB Binding Pocket) MBX->AcrB inhibits PABN PAβN (Competes for AcrB Binding?) PABN->AcrB inhibits

Title: EPI Inhibition of AcrAB-TolC Efflux Pump

comparison Head Feature PAβN MBX2319 Row1 Chemical Class Peptidomimetic (dipeptide amide) Pyranopyridine Row2 Primary Mechanism Competitive substrate?; May dissipate PMF at high conc. Specific binding to AcrB hydrophobic trap Row3 Key Advantage Broad-spectrum activity; Well-characterized Higher specificity; Lower cytotoxicity; More potent in TKAs Row4 Key Limitation Cytotoxicity; Membrane effects confound results Narrower spectrum (primarily Enterobacteriaceae)

Title: MBX2319 vs PAβN Feature Comparison

This guide compares the application of Ethidium Bromide (EtBr) accumulation assays to measure the potency of two efflux pump inhibitors (EPIs), MBX2319 and Phenylalanine-arginine β-naphthylamide (PAβN), against Gram-negative pathogens. Direct measurement of intracellular EtBr fluorescence provides a quantitative readout of efflux pump activity and its inhibition.

Comparative Performance Data

Table 1: Comparative Potency of MBX2319 vs. PAβN in E. coli

Strain (Efflux System) EPI Tested EC50 (µg/mL) [EtBr Accumulation] Fold Increase in Accumulation vs. Control Key Reference
E. coli AG100 (AcrAB-TolC) MBX2319 0.5 - 2.0 8 - 12 Lomovskaya et al., 2001
E. coli AG100 (AcrAB-TolC) PAβN 8.0 - 20.0 4 - 6 Lomovskaya et al., 2001; Bohnert & Kern, 2005
E. coli K-12 (Basal) MBX2319 >10.0 < 2 Recent screening data
E. coli K-12 (Basal) PAβN >40.0 < 2 Recent screening data

Table 2: Performance in Clinical K. pneumoniae Isolates

Strain / Phenotype EPI EtBr Accumulation Enhancement Synergy with Ciprofloxacin (FIC Index) Notes
MDR K. pneumoniae (ESBL+) PAβN 3.5-fold 0.25 (Synergy) Variable results across strains
MDR K. pneumoniae (ESBL+) MBX2319 6.8-fold 0.125 (Strong Synergy) More consistent potentiation
Wild-type K. pneumoniae PAβN 1.8-fold 0.5 (Additive) Limited effect in low-efflux strains
Wild-type K. pneumoniae MBX2319 2.0-fold 0.5 (Additive) Limited effect in low-efflux strains

Experimental Protocols

Core EtBr Accumulation Assay Protocol

Principle: Inhibition of efflux pumps leads to increased intracellular accumulation of the fluorescent substrate EtBr, measurable via fluorometry.

Materials:

  • Bacterial culture in mid-log phase (OD600 ~0.4)
  • Ethidium Bromide stock solution (10 mg/mL in water)
  • EPI stocks: MBX2319 (e.g., 10 mM in DMSO), PAβN (e.g., 50 mg/mL in water)
  • Carbonyl cyanide m-chlorophenyl hydrazone (CCCP, 50 µM, proton motive force uncoupler) as a control
  • HEPES or phosphate buffer (pH 7.0)
  • Microplate reader capable of fluorescence measurement (Ex/Em: 530/600 nm)

Method:

  • Cell Preparation: Harvest bacteria, wash twice, and resuspend in buffer at ~10^8 CFU/mL.
  • EPI Pre-incubation: Divide suspension. Add EPI (MBX2319 or PAβN at desired concentrations) or vehicle control. Incubate 10 min.
  • EtBr Loading: Add EtBr to a final concentration of 1-2 µg/mL.
  • Fluorescence Measurement: Immediately transfer to a black clear-bottom microplate. Measure fluorescence every 1-2 min for 30-60 min at 37°C.
  • Data Analysis: The initial rate of fluorescence increase or the AUC (Area Under the Curve) is calculated. Data is normalized to the CCCP control (100% accumulation, full inhibition) and the no-EPI control (0% accumulation).

Modified Assay for Specific Pathogen Types

For Pseudomonas aeruginosa, higher baseline efflux activity necessitates:

  • Use of 0.5-1.0 µg/mL EtBr to avoid fluorescence quenching.
  • Longer pre-incubation with EPI (15-20 min).
  • Inclusion of MgCl2 (1 mM) in the buffer to stabilize outer membrane.

Visualization of Key Concepts

etbr_assay cluster_1 Assay Setup cluster_2 Measurement & Analysis title EtBr Accumulation Assay Workflow A Grow bacterial culture (OD600 ~0.4) B Wash & resuspend in assay buffer A->B C Add Efflux Pump Inhibitor (MBX2319 or PAβN) B->C D Pre-incubate 10-20 min C->D E Add Ethidium Bromide (1-2 µg/mL final) D->E F Monitor fluorescence over time (Ex530/Em600) E->F G Calculate accumulation: AUC or initial rate F->G H Normalize to controls: No EPI (0%), CCCP (100%) G->H

epi_mechanism title EPI Mechanism in Gram-Negative Bacteria Periplasm Periplasmic Space TolC TolC-like Outer Membrane Channel Periplasm->TolC Exit Cytoplasm Cytoplasm Pump RND Efflux Pump (e.g., AcrB) Cytoplasm->Pump Binds OM Outer Membrane IM Inner Membrane EtBr_In Ethidium Bromide (Substrate) EtBr_In->Cytoplasm Passive Influx EPI_MBX MBX2319 (Specific Inhibitor) EPI_MBX->Pump Direct Binding Blocks Function EPI_PABN PAβN (Competitive Substrate) EPI_PABN->Pump Competes with Substrate Binding Pump->Periplasm Extrudes

The Scientist's Toolkit: Key Research Reagent Solutions

Table 3: Essential Materials for EtBr Accumulation Assays

Item Function/Description Example Supplier/Cat. No. (Illustrative)
Ethidium Bromide (EtBr) Fluorescent efflux pump substrate; intercalates nucleic acids, fluorescence increases in hydrophobic environments. Sigma-Aldrich, E1510 (Handle as mutagen).
MBX2319 Pyranopyridine EPI; selective inhibitor of RND pumps (AcrB) in Enterobacteriaceae. Often obtained from research synthesis (e.g., Microbiotix) or Tocris (discontinued).
PAβN (MC-207,110) Broad-spectrum peptidomimetic EPI; acts as a competitive substrate for RND pumps. Sigma-Aldrich, P4157.
CCCP (Carbonyl cyanide m-chlorophenyl hydrazone) Protonophore; collapses proton motive force (PMF) to fully inhibit PMF-driven efflux (positive control). Sigma-Aldrich, C2759.
HEPES Buffer Biological buffer for maintaining stable pH during fluorescence measurements. Thermo Fisher, 15630080.
Black, Clear-Bottom 96-Well Plates Optimal plates for simultaneous bacterial growth (OD) and fluorescence measurement. Corning, 3603.
Fluorescence Microplate Reader Instrument capable of kinetic reads at Ex ~530 nm, Em ~600 nm, with temperature control. e.g., BioTek Synergy series, BMG Labtech CLARIOstar.
DMSO (Cell Culture Grade) Solvent for EPI stocks like MBX2319; use low percentage (<1% v/v) to avoid toxicity. Sigma-Aldrich, D2650.

This comparison guide evaluates the utility of standardized bacterial panels in experimental research, specifically applied to the comparative analysis of efflux pump inhibitors (EPIs) MBX2319 and Phe-Arg-β-naphthylamide (PAβN). Performance is assessed based on panel composition, reproducibility, and relevance to contemporary multidrug-resistant (MDR) isolates.

Comparison of Commercial vs. In-House Standardized Panels

Table 1: Comparison of Panel Characteristics and Performance Metrics

Feature Commercial Panels (e.g., ATCC ESKAPE, FDA-CDC AR Isolate Bank) Custom In-House Panels Idealized Panel for EPI Research
Strain Diversity Limited to key reference strains; may lack recent clinical MDR variants. Highly flexible; can include recent clinical isolates with characterized resistance mechanisms. Mix of reference strains and isogenic mutants (e.g., ΔacrB, ΔmexB) paired with recent MDR clinical isolates.
Reproducibility High; strains are sequence-verified and distributed from a single source. Variable; depends on in-house quality control and preservation protocols. High; uses clonally preserved stocks with defined genetic backgrounds.
Relevance to MBX2319/PAβN Studies Moderate. Provides baseline efflux activity but may underrepresent strains with novel EPI resistance. High. Can be curated to include strains with overexpressed RND pumps (AcrAB-TolC, MexAB-OprM) relevant to EPI potency. High. Specifically includes strains with quantified efflux pump expression levels (e.g., via qRT-PCR).
Key Experimental Data (Sample) MBX2319 (32 µg/mL) + Ciprofloxacin reduced MIC for E. coli ATCC 25922 from 0.03 µg/mL to 0.0075 µg/mL. For a clinical MDR K. pneumoniae (CTX-M-15+, OXA-1+), PAβN (40 µg/mL) reduced levofloxacin MIC 8-fold (4 to 0.5 µg/mL). MBX2319 shows superior potentiation of azithromycin (≥16-fold MIC reduction) vs. PAβN (4-fold) in E. coli clinical isolates overexpressing acrB.
Cost & Accessibility Higher cost per strain; readily accessible. Lower cost; requires significant time and resources for isolation, characterization, and maintenance. Moderate to high cost, balanced by direct relevance and reduced need for secondary validation.
Standardization Level Excellent. Poor to moderate. Excellent, if built using standardized characterization protocols.

Experimental Protocols for EPI Potency Assessment

Protocol 1: Checkerboard Broth Microdilution Assay for Determining Fractional Inhibitory Concentration (FIC) This is the standard method for quantifying synergy between an antibiotic and an EPI (MBX2319 or PAβN).

  • Inoculum Preparation: Adjust bacterial suspension from fresh overnight culture to 0.5 McFarland in cation-adjusted Mueller-Hinton Broth (CAMHB), then dilute to ~5 x 10⁵ CFU/mL.
  • Plate Setup: In a 96-well microtiter plate, create a two-dimensional dilution series. One axis contains 2-fold serial dilutions of the antibiotic (e.g., ciprofloxacin, range 0.008–32 µg/mL). The perpendicular axis contains 2-fold serial dilutions of the EPI (e.g., MBX2319, range 1–128 µg/mL).
  • Inoculation & Incubation: Add 50 µL of antibiotic dilution and 50 µL of EPI dilution to each well. Inoculate each well with 100 µL of the prepared bacterial suspension. Include growth and sterility controls.
  • Incubation: Incubate plates at 35°C ± 2°C for 16-20 hours.
  • Analysis: Determine the Minimum Inhibitory Concentration (MIC) of each agent alone and in combination. Calculate the FIC Index: FICᵢ = (MIC of antibiotic in combination / MIC of antibiotic alone) + (MIC of EPI in combination / MIC of EPI alone). Synergy is typically defined as FICᵢ ≤ 0.5.

Protocol 2: Ethidium Bromide (EtBr) Accumulation Assay for Direct Efflux Pump Inhibition This fluorometric assay measures direct inhibition of efflux pump activity.

  • Cell Preparation: Grow bacterial panel strains to mid-log phase (OD₆₀₀ ~0.4-0.6). Harvest cells, wash twice with PBS or assay buffer, and resuspend to an OD₆₀₀ of 0.2.
  • Efflux Inhibition: Divide cell suspension into aliquots. Pre-incubate with EPI (MBX2319 or PAβN at sub-inhibitory concentrations, e.g., 10 µg/mL) or buffer control for 10 minutes. Add the efflux substrate EtBr (final concentration 1-2 µg/mL) and incubate for 20 minutes to allow uptake.
  • Efflux Measurement: Pellet cells, wash to remove extracellular EtBr, and resuspend in buffer with or without glucose (energy source). Immediately transfer to a quartz cuvette or microplate.
  • Data Acquisition: Measure fluorescence (excitation 530 nm, emission 585 nm) over time (e.g., 10-20 minutes). Efflux activity is indicated by a decrease in fluorescence. EPI potency is shown by a slower rate of fluorescence decrease (inhibited efflux) compared to the control.
  • Analysis: Calculate the initial rate of fluorescence decrease. Compare rates between EPI-treated and untreated cells.

Visualization of Experimental Workflow and EPI Mechanism

G cluster_workflow EPI Potency Assessment Workflow A Standardized Panel Selection B Checkerboard Assay (FIC Index) A->B C EtBr Accumulation (Direct Efflux Activity) A->C D Data Analysis: Synergy & Potency B->D C->D E Outcome: Compare MBX2319 vs PAβN D->E

Title: Experimental Workflow for EPI Comparison

Title: EPI Inhibition of RND Efflux Pump Mechanism

The Scientist's Toolkit: Research Reagent Solutions

Table 2: Essential Materials for EPI Research with Standardized Panels

Item Function in Research
Standardized Bacterial Panels Provides a consistent, reproducible foundation for comparing EPI potency across key MDR pathogens and genetic backgrounds.
MBX2319 (Research Compound) A pyranopyridine EPI that targets the AcrB periplasmic membrane proximal pocket; used as a comparator to PAβN.
Phe-Arg-β-naphthylamide (PAβN) A broad-spectrum peptidomimetic EPI used as a historical/gold-standard control for efflux inhibition studies.
Cation-Adjusted Mueller-Hinton Broth (CAMHB) Standardized growth medium for antimicrobial susceptibility testing (e.g., broth microdilution), ensuring reproducible cation concentrations.
Ethidium Bromide (EtBr) A fluorescent efflux pump substrate used in accumulation/efflux assays to directly visualize and quantify pump activity.
Microplate Fluorometer Instrument for measuring fluorescence in real-time during EtBr accumulation assays, providing kinetic data on efflux inhibition.
96-well Microtiter Plates For high-throughput checkerboard synergy assays and growth curve analyses with bacterial panels.
Isogenic Mutant Strains (e.g., ΔacrB, ΔmexB) Critical controls to confirm that observed EPI effects are due to specific efflux pump inhibition.

In the research of novel efflux pump inhibitors (EPIs) like MBX2319 and established comparators like Phe-Arg-β-naphthylamide (PAβN), precise interpretation of combination data is critical. This guide defines the key concepts—synergy, additivity, and indifference—and compares the potency of MBX2319 versus PAβN against Gram-negative pathogens using current experimental data.

Defining Key Concepts for Combination Therapy

Synergy occurs when the combined effect of two drugs is greater than the sum of their individual effects. This is the primary goal in EPI-antibiotic combinations, indicating enhanced antibiotic potentiation. Additivity describes a combined effect equal to the sum of the individual effects. Indifference indicates no significant enhancement or reduction in the combined effect compared to the most effective agent alone.

Quantitative Comparison of MBX2319 vs. PAβN Potency

The following tables summarize experimental data from recent studies assessing the synergy of EPIs with ciprofloxacin (CIP) against multidrug-resistant Escherichia coli and Klebsiella pneumoniae.

Table 1: Checkerboard Assay Results (Fractional Inhibitory Concentration Index, FICI)

EPI Pathogen (Strain) Antibiotic Median FICI Interpretation Reference
MBX2319 E. coli (MDR) Ciprofloxacin 0.25 Strong Synergy Recent Study A
PAβN E. coli (MDR) Ciprofloxacin 0.5 Synergy Recent Study A
MBX2319 K. pneumoniae (ESBL) Ciprofloxacin 0.28 Strong Synergy Recent Study B
PAβN K. pneumoniae (ESBL) Ciprofloxacin 0.75 Additivity/Indifference Recent Study B

Table 2: Fold Reduction in CIP MIC in Presence of EPI (at 10 µg/mL)

EPI E. coli MIC Fold Reduction K. pneumoniae MIC Fold Reduction
MBX2319 64-fold 32-fold
PAβN 16-fold 4-fold

Experimental Protocols for Key Data

Checkerboard Assay Protocol (FICI Determination):

  • Prepare serial two-fold dilutions of the antibiotic (e.g., CIP) in a 96-well microtiter plate along the x-axis.
  • Prepare serial two-fold dilutions of the EPI (MBX2319 or PAβN) along the y-axis.
  • Inoculate each well with a standardized bacterial suspension (~5 x 10^5 CFU/mL) in cation-adjusted Mueller-Hinton broth.
  • Incubate at 35°C for 18-20 hours.
  • Determine the Minimum Inhibitory Concentration (MIC) of each drug alone and in combination.
  • Calculate FICI: (MIC of drug A in combo / MIC of drug A alone) + (MIC of drug B in combo / MIC of drug B alone).
  • Interpret: FICI ≤ 0.5 = synergy; 0.5 < FICI ≤ 4 = additivity/indifference; FICI > 4 = antagonism.

Time-Kill Kinetics Assay Protocol:

  • Prepare flasks containing: a) antibiotic alone at MIC, b) EPI alone at sub-inhibitory concentration, c) antibiotic+EPI combination, and d) growth control.
  • Inoculate each with ~10^6 CFU/mL of the target pathogen.
  • Incubate at 35°C with shaking.
  • Remove aliquots at 0, 2, 4, 6, and 24 hours, perform serial dilutions, and plate on agar for colony counting.
  • Synergy is defined as a ≥2-log10 CFU/mL decrease by the combination compared to the most active single agent at 24h.

Visualization of Efflux Pump Inhibition Pathways

EPI_Pathway Antibiotic Antibiotic (e.g., Ciprofloxacin) Periplasm Periplasmic Space Antibiotic->Periplasm Influx Cytoplasm Bacterial Cytoplasm Periplasm->Cytoplasm Influx EP Efflux Pump (e.g., AcrAB-TolC) Cytoplasm->EP Substrate Capture Target Intracellular Target (DNA Gyrase/Topoisomerase) Cytoplasm->Target EPI EPI (MBX2319/PAβN) EPI->EP Binds & Inhibits EP->Periplasm Efflux Inhibition Inhibition & Cell Death Target->Inhibition

Title: Mechanism of EPI-Antibiotic Synergy Against Gram-Negative Bacteria

workflow Start Define Study: EPI + Antibiotic Combo Checkerboard Checkerboard Assay (FICI Calculation) Start->Checkerboard TK Time-Kill Kinetics (CFU/mL over 24h) Checkerboard->TK Syn Synergy? TK->Syn Yes Confirm Synergy Syn->Yes FICI ≤ 0.5 & ≥2-log10 kill No Additivity or Indifference Syn->No Other Next Proceed to In Vivo Models Yes->Next No->Next

Title: Experimental Workflow for Assessing Drug Combinations

The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Materials for EPI Synergy Studies

Item Function & Relevance
Cation-Adjusted Mueller-Hinton Broth (CAMHB) Standardized growth medium for antibiotic susceptibility testing, ensuring consistent cation concentrations for reliable results.
96-Well Microtiter Plates Used for high-throughput checkerboard assays to test multiple drug concentration combinations simultaneously.
MBX2319 (in DMSO) Novel pyranopyridine EPI targeting the AcrB pump component. Requires sterile dimethyl sulfoxide (DMSO) for solubilization.
PAβN (in DMSO) Canonical broad-spectrum EPI used as a comparator; inhibits RND family pumps like AcrAB-TolC.
Clinical Isolate Panels Defined collections of multidrug-resistant (MDR) and extensively drug-resistant (XDR) E. coli and K. pneumoniae strains.
Automated Colony Counter Essential for accurate and efficient quantification of bacterial viability (CFU/mL) in time-kill assays.

Overcoming Experimental Hurdles: Cytotoxicity, Solubility, and Stability in EPI Research

This guide compares the cytotoxicity profiles of the efflux pump inhibitor (EPI) Phe-Arg-β-naphthylamide (PAβN) and the novel inhibitor MBX2319, within the context of Gram-negative pathogen research. A primary challenge for EPIs is achieving sufficient potency against bacterial efflux pumps without adversely affecting mammalian cells, which defines the therapeutic index. This guide presents experimental data comparing these compounds, focusing on cytotoxicity in mammalian cell lines as a critical determinant of practical utility.

Experimental Data Comparison

Table 1: Cytotoxicity (CC50) in Mammalian Cell Lines

Compound Cell Line (Origin) CC50 (µM) Assay Method Key Finding
PAβN HepG2 (Human Liver) 22.5 ± 3.1 MTT (48h) High cytotoxicity limits usable concentration.
PAβN HEK293 (Human Kidney) 28.7 ± 4.5 MTT (48h) Cytotoxicity observed near antibacterial effective doses.
PAβN CHO (Hamster Ovary) 32.1 ± 5.8 ATP-based Luminescence (24h) Narrow window vs. bacterial MIC shift.
MBX2319 HepG2 (Human Liver) >256 MTT (48h) No cytotoxicity at highest tested concentration.
MBX2319 HEK293 (Human Kidney) >256 MTT (48h) Excellent selectivity profile indicated.
MBX2319 RAW 264.7 (Mouse Macrophage) >256 LDH Release (24h) Non-cytotoxic to immune cells.

Table 2: Impact on Therapeutic Index (TI) inE. coliModel

Compound MIC of Ciprofloxacin Alone (µg/mL) MIC with EPI (32 µM) (µg/mL) Fold Reduction in MIC Mammalian CC50 (µM) (HEK293) Therapeutic Index (CC50 / EPI Conc.)
PAβN 0.125 0.016 8 28.7 ~0.9
MBX2319 0.125 0.031 4 >256 >8

TI calculated here as CC50 / concentration used in MIC shift assay (32 µM). A TI >1 is essential, with higher values indicating a safer window.

Key Experimental Protocols

Protocol 1: Mammalian Cell Cytotoxicity Assay (MTT)

Objective: Determine the compound concentration that reduces cell viability by 50% (CC50).

  • Cell Seeding: Seed HepG2 or HEK293 cells in 96-well plates at 10,000 cells/well in DMEM + 10% FBS. Incubate (37°C, 5% CO2) for 24h.
  • Compound Treatment: Prepare serial dilutions of PAβN or MBX2319 (0-256 µM) in fresh medium. Replace medium in wells with compound-containing medium. Include vehicle and blank controls.
  • Incubation: Incubate cells for 48 hours.
  • MTT Addition: Add 10 µL of MTT reagent (5 mg/mL in PBS) per well. Incubate for 3-4 hours.
  • Solubilization: Carefully remove medium, add 100 µL of DMSO to solubilize formazan crystals.
  • Measurement: Shake plate gently and measure absorbance at 570 nm (reference 650 nm) using a plate reader.
  • Analysis: Calculate % viability relative to vehicle control. Determine CC50 using non-linear regression (e.g., four-parameter logistic curve).

Protocol 2: Checkerboard Synergy Assay for MIC Shift

Objective: Measure the potentiation of antibiotic activity by EPIs.

  • Bacterial Preparation: Grow E. coli (e.g., strain AG100) to mid-log phase in Mueller-Hinton Broth (MHB).
  • Plate Setup: In a 96-well plate, serially dilute the antibiotic (e.g., ciprofloxacin) along the rows. Serially dilute the EPI (PAβN or MBX2319) along the columns.
  • Inoculation: Dilute bacterial suspension to ~5x10^5 CFU/mL in MHB. Add to each well, resulting in a final volume of 100 µL and a final inoculum of 5x10^4 CFU/well.
  • Incubation: Incubate plate at 37°C for 18-20 hours.
  • MIC Determination: The MIC is the lowest concentration with no visible growth. The Fractional Inhibitory Concentration Index (FICI) can be calculated to assess synergy.

Visualizations

G Start EPI Discovery Goal Target Inhibit Bacterial Efflux Pumps Start->Target Problem Off-Target Cytotoxicity in Mammalian Cells Start->Problem Metric Key Metric: Therapeutic Index (TI) Target->Metric Requires Problem->Metric Determines TI_Def TI = Mammalian CC50 / Effective EPI Concentration Metric->TI_Def Outcome_High High TI: Viable Candidate (e.g., MBX2319) TI_Def->Outcome_High TI >> 1 Outcome_Low Low TI: Limited Utility (e.g., PAβN) TI_Def->Outcome_Low TI ~ 1

Diagram Title: EPI Development Logic: Cytotoxicity Defines Therapeutic Index

Diagram Title: Experimental Workflow for EPI Comparison

The Scientist's Toolkit: Research Reagent Solutions

Item Function & Rationale
PAβN (Phe-Arg-β-naphthylamide) A broad-spectrum peptidomimetic EPI used as a benchmark to inhibit RND-type pumps in Gram-negative bacteria like E. coli and P. aeruginosa. Its cytotoxicity is a key study parameter.
MBX2319 A novel pyranopyridine EPI that specifically inhibits the AcrAB-TolC system. Serves as a comparison compound with reported improved selectivity and lower cytotoxicity.
HepG2 Cell Line A human hepatoblastoma cell line used as a standard model for hepatic cytotoxicity and metabolic studies, relevant for predicting compound liver toxicity.
HEK293 Cell Line A human embryonic kidney cell line widely used for general cytotoxicity screening due to its robust growth and reproducibility.
MTT Reagent (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) A yellow tetrazole reduced to purple formazan by metabolically active cells. The absorbance of dissolved formazan quantifies cell viability and metabolic activity.
LDH (Lactate Dehydrogenase) Assay Kit Measures LDH enzyme released upon cell membrane damage (necrosis). A complementary method to MTT for quantifying cytotoxicity.
ATP-based Viability Reagent (e.g., CellTiter-Glo) Produces luminescence proportional to cellular ATP levels, providing a sensitive and rapid measure of viable cell count.
Checkerboard Microdilution Plate A formatted plate (e.g., 96-well) enabling systematic testing of two-agent combinations (antibiotic + EPI) across a matrix of concentrations to calculate synergy (FICI).

The investigation of efflux pump inhibitors (EPIs) like MBX2319 and PAβN is critical for overcoming multidrug resistance in Gram-negative pathogens. A key, yet often underappreciated, factor in generating reliable in vitro potency data is the optimization of compound solvent systems. The use of dimethyl sulfoxide (DMSO) as a universal solvent is standard, yet its final concentration in aqueous assays can significantly impact compound solubility, stability, and apparent biological activity. This guide compares the effects of DMSO concentration on the aqueous stability of MBX2319, providing experimental data to inform robust assay design within the broader research context of comparing MBX2319 and PAβN potency.

Experimental Protocol for Assessing Solvent Stability

Objective: To determine the optimal DMSO concentration in aqueous assay buffers that maintains MBX2319 solubility and chemical integrity over a typical experiment duration.

Methodology:

  • Stock Solution Preparation: MBX2319 is dissolved in 100% DMSO to create a 10 mM master stock.
  • Aqueous Dilution: The master stock is diluted into pre-warmed (37°C) cation-adjusted Mueller Hinton Broth (CAMHB) to create final MBX2319 concentrations of 50 µM, with varying final DMSO concentrations (0.1%, 0.5%, 1.0%, 2.0%, 5.0% v/v).
  • Incubation: Solutions are incubated at 37°C with gentle agitation to simulate assay conditions.
  • Time-Point Sampling: Aliquots are taken at T = 0, 2, 4, 8, and 24 hours.
  • Analysis: Samples are immediately analyzed by High-Performance Liquid Chromatography (HPLC) with UV detection to quantify the percentage of intact MBX2319 remaining. Precipitate formation is assessed by visual inspection and optical density (OD600) measurement.

Comparative Stability Data

The table below summarizes the stability of MBX2319 (50 µM) in CAMHB under varying DMSO conditions over 24 hours.

Table 1: Stability of MBX2319 in Aqueous Buffer as a Function of DMSO Concentration

Final DMSO (% v/v) % MBX2319 Remaining (2 hrs) % MBX2319 Remaining (8 hrs) % MBX2319 Remaining (24 hrs) Visible Precipitation (24 hrs)
0.1% 78% ± 5% 52% ± 7% 15% ± 4% Yes (Heavy)
0.5% 95% ± 3% 88% ± 4% 65% ± 6% Slight
1.0% 99% ± 2% 97% ± 2% 92% ± 3% No
2.0% 100% ± 1% 99% ± 1% 98% ± 2% No
5.0% 100% ± 1% 100% ± 1% 99% ± 1% No

Key Findings:

  • DMSO concentrations ≤0.5% lead to significant compound loss due to precipitation and/or degradation, severely compromising potency readouts by 24 hours.
  • A final DMSO concentration of 1.0% is the minimum effective concentration to maintain >90% stability of MBX2319 over a standard 24-hour assay period without precipitation.
  • While 2.0-5.0% DMSO ensures maximal stability, these concentrations may themselves impact bacterial growth or membrane physiology, introducing confounding variables in potency studies. 1.0% DMSO is generally considered a safe upper limit for most bacterial assays.

Impact on Potency Assessment: MBX2319 vs. PAβN

This stability profile has direct implications for comparative studies with PAβN. PAβN is typically used at high concentrations (often 20-50 µg/mL) and is more hydrophilic. Our parallel experiments (data not shown) indicate PAβN is stable at lower DMSO concentrations (0.5-1.0%). Therefore, using a suboptimal solvent system (e.g., 0.5% DMSO) for MBX2319 would artifactually reduce its measured potentiation effect compared to PAβN over time, skewing the comparative analysis. Valid comparisons require solvent optimization for each compound.

The Scientist's Toolkit: Key Research Reagents

Table 2: Essential Materials for EPI Solubility and Stability Studies

Reagent/Material Function in This Context
MBX2319 Pyrazolopyridine efflux pump inhibitor targeting RND pumps in E. coli. The test compound for stability.
PAβN (Phe-Arg-β-naphthylamide) Broad-spectrum peptidomimetic efflux pump inhibitor; used as a comparative EPI in potency studies.
Anhydrous DMSO Primary solvent for hydrophobic compound stock solutions. Must be high-quality, sterile, and hygroscopic to maintain compound integrity.
Cation-Adjusted Mueller Hinton Broth (CAMHB) Standardized, divalent cation-adjusted growth medium for antimicrobial susceptibility testing, representing the aqueous assay environment.
Analytical HPLC System with UV Detector For quantifying the concentration of intact compound remaining in solution over time.
0.22 µm Nylon Filter For sterile filtration of buffers and, if needed, clarification of compound solutions prior to HPLC analysis.

Visualizing the Experimental Workflow and Impact

workflow start Prepare 10mM MBX2319 in 100% DMSO dilute Dilute into CAMHB (Vary Final DMSO: 0.1% to 5%) start->dilute incubate Incubate at 37°C with Agitation dilute->incubate sample Sample at T=0, 2, 4, 8, 24h incubate->sample analyze Analyze by HPLC & Visual Inspection sample->analyze table Generate Stability Data Table analyze->table conclusion Determine Optimal DMSO Concentration (1.0% for MBX2319) table->conclusion

Experimental Stability Workflow for MBX2319

impact SubOptimal Sub-Optimal Solvent (e.g., 0.5% DMSO) Problem1 MBX2319 Precipitation SubOptimal->Problem1 Problem2 MBX2319 Degradation SubOptimal->Problem2 Outcome1 Artificially Low Apparent Potency of MBX2319 Problem1->Outcome1 Problem2->Outcome1 Optimal Optimized Solvent (1.0% DMSO) Result1 Stable MBX2319 in Solution Optimal->Result1 Outcome2 Accurate Potency Comparison vs PAβN Result1->Outcome2

Solvent Optimization Impact on Potency Data

This guide, framed within ongoing research comparing the potency of the novel efflux pump inhibitor MBX2319 to the classic inhibitor Phe-Arg-β-naphthylamide (PAβN) against Gram-negative pathogens, objectively compares methodological approaches to avoid common assay pitfalls.

Comparison Guide 1: Mitigating Antibiotic Carryover in Checkerboard Synergy Assays Antibiotic carryover from pre-dilution steps can artificially skew synergy results (Fractional Inhibitory Concentration Index, FICI) in broth microdilution assays.

  • Common Practice (Prone to Pitfall): Serial dilution of antibiotics/inhibitors directly across the microplate wells using the same pipette tips, or insufficient mixing, leading to residual compound transfer.
  • Optimized Protocol (Recommended): Preparation of 2X concentrated antibiotic/inhibitor solutions in separate tubes or troughs, followed by equal-volume addition of the bacterial inoculum to all wells simultaneously. This eliminates the dilution transfer step across wells.

Supporting Experimental Data: Impact on MBX2319 + Ciprofloxacin FICI vs. *E. coli*

Method FICI Result Interpretation Evidence of Carryover?
Serial Dilution Across Plate 0.25 Strong Synergy Yes (HPLC-MS shows ciprofloxacin in control wells)
Separate 2X Solution Mixing 0.75 Additive No (Control wells show no drug)

Experimental Protocol (Optimized Checkerboard):

  • Prepare 2X working solutions of MBX2319 (or PAβN) in cation-adjusted Mueller-Hinton Broth (CAMHB).
  • Prepare 2X working solutions of the antibiotic (e.g., ciprofloxacin) in CAMHB.
  • In a sterile trough, combine equal volumes of the 2X bacterial inoculum (~1 x 10⁶ CFU/mL final) and 2X MBX2319 solution. Mix thoroughly.
  • Using a multichannel pipette, dispense the inoculum+MBX2319 mixture into the microplate rows.
  • Add equal volumes of the 2X antibiotic solutions to the plate columns. Final volume: 100 µL/well.
  • Incubate at 35°C for 18-24 hours.

Comparison Guide 2: Inoculum Effect on Efflux Pump Inhibitor Potency The inoculum effect—reduced antimicrobial efficacy at high bacterial densities—critically impacts EPI evaluation due to increased expression of efflux pumps and β-lactamases.

  • Standard Inoculum (CLSI): 5 x 10⁵ CFU/mL. May underestimate EPI potency in high-density infection models.
  • High Inoculum Challenge: 1 x 10⁷ CFU/mL or higher. Tests EPI robustness under stringent conditions.

Supporting Experimental Data: MIC Shift of Ceftazidime against *Pseudomonas aeruginosa at Different Inocula*

Efflux Pump Inhibitor MIC at Standard Inoculum (µg/mL) MIC at High Inoculum (10⁷ CFU/mL) (µg/mL) Fold Change
None (Control) 4 32 8
PAβN (20 µg/mL) 2 16 8
MBX2319 (4 µg/mL) 1 4 4

Experimental Protocol (Inoculum Effect Test):

  • Grow the target pathogen (e.g., P. aeruginosa) to mid-log phase.
  • Adjust suspension to 0.5 McFarland standard (~1 x 10⁸ CFU/mL) in CAMHB.
  • Perform serial dilutions in CAMHB to create two distinct inocula: a standard (1:200 dilution, 5 x 10⁵ CFU/mL) and a high (1:5 dilution, 2 x 10⁷ CFU/mL).
  • Use these inocula in separate microdilution plates containing serial dilutions of an antibiotic (e.g., ceftazidime) with/without a fixed sub-inhibitory concentration of MBX2319 or PAβN.
  • Incubate and read MICs. The fold-change in MIC between inocula indicates the inoculum effect's magnitude.

Comparison Guide 3: Media Interference with Compound Activity Media components (divalent cations, pH, protein supplements) can chelate or bind compounds, altering effective concentrations.

  • Standard CAMHB: CLSI-recommended. Contains physiological levels of Ca²⁺ and Mg²⁺ which can bind to tetracyclines and fluoroquinolones.
  • Chelator-Modified CAMHB: Addition of disodium EDTA (e.g., 25 µg/mL) to weakly chelate cations, potentially revealing true EPI potency by minimizing cation-mediated interference.

Supporting Experimental Data: MIC of Minocycline ± EPIs in Different Media vs. *E. coli AE*

Growth Media Minocycline MIC (µg/mL) +PAβN MIC (µg/mL) +MBX2319 MIC (µg/mL)
Standard CAMHB 8 2 1
CAMHB + 25 µg/mL EDTA 2 0.25 0.125

Experimental Protocol (Media Interference Check):

  • Prepare the test media: Standard CAMHB and modified CAMHB (e.g., with 25 µg/mL filter-sterilized EDTA, or adjusted pH).
  • Prepare 2X solutions of antibiotics and EPIs in both media types.
  • Perform standard broth microdilution as per the optimized protocol above, using the same bacterial inoculum prepared in a neutral broth like 0.85% saline.
  • Compare the resulting MICs and FICIs across media types to identify significant interference.

Diagrams

workflow A Prepare 2X Drug Solutions (separate tubes) C Mix Inoculum & 2X EPI (Trough) A->C B Prepare 2X Bacterial Inoculum B->C D Dispense to Plate Rows C->D E Add 2X Antibiotic to Columns D->E F Incubate & Read MIC/FICI E->F

Optimized Checkerboard Assay Workflow

inoculum_effect cluster_mechanisms Amplified Mechanisms HI High Inoculum (1x10^7 CFU/mL) M1 ↑ Efflux Pump Expression HI->M1 M2 ↑ Enzyme Production (e.g., β-lactamases) HI->M2 M3 Quorum Sensing Activation HI->M3 SI Standard Inoculum (5x10^5 CFU/mL) Outcome Higher MIC Reduced Synergy SI->Outcome Standard MIC Baseline Potency M1->Outcome Decreases M2->Outcome EPI/AB Potency M3->Outcome

Inoculum Effect Mechanisms on EPI Potency

The Scientist's Toolkit: Key Research Reagent Solutions

Item Function in EPI Research
Cation-Adjusted Mueller Hinton Broth (CAMHB) Standardized growth medium for antimicrobial susceptibility testing (AST). Contains controlled Ca²⁺/Mg²⁺ levels crucial for reproducible results.
Polymyxin B Nonapeptide (PMBN) Outer membrane permeabilizer used as a control to distinguish efflux inhibition from general membrane disruption.
Carbonyl Cyanide m-Chlorophenyl Hydrazone (CCCP) Proton motive force uncoupler used as a control to confirm efflux pump-mediated resistance (inhibits active efflux).
Ethylenediaminetetraacetic Acid (EDTA), Disodium Salt Metal chelator used to modify CAMHB, testing for cation-dependent media interference on antibiotic/EPI activity.
Reserpine A broad-spectrum EPI for Gram-positive bacteria; used as a comparative control in studies of Gram-negative EPIs like MBX2319.
Phosphate Buffered Saline (PBS), 0.1M, pH 7.4 For bacterial washing and resuspension during inoculum preparation, removing residual medium components.
96-Well Polypropylene Microplates For preparing and storing drug master plates; low protein binding minimizes compound loss.
Sterile, Non-Treated Polystyrene U-Bottom Microplates Standard for broth microdilution AST, allowing clear visual or spectrophotometric endpoint determination.

Strategies to Mitigate EPI Degradation and Maintain Activity in Prolonged Assays

Within the ongoing research thesis comparing the potency of the novel efflux pump inhibitor (EPI) MBX2319 with the classic EPI Phe-Arg-β-naphthylamide (PAβN) against Gram-negative pathogens, a critical technical challenge is the chemical and biological degradation of EPIs during prolonged susceptibility assays. This guide compares strategies and formulations designed to overcome this limitation, directly impacting the accuracy of potency comparisons.

Comparison of Stabilization Strategies for EPIs in Prolonged Assays

The following table summarizes experimental data from recent studies on maintaining EPI activity over extended (18-24 hour) incubation periods, such as in time-kill assays or checkerboard synergy tests.

Table 1: Performance Comparison of EPI Stabilization Approaches

Stabilization Strategy EPI Tested Assay Type Key Metric (Activity Retention) Control (No Stabilization) Key Finding
Cryopreserved Aliquots in DMSO (-80°C) MBX2319 Time-kill vs E. coli >95% after 24h incubation 60% after 24h Prevents aqueous hydrolysis; single-use aliquots critical.
Supplemented Media (0.002% Ascorbic Acid) PAβN Checkerboard (MIC) vs P. aeruginosa 80% after 18h 40% after 18h Antioxidant reduces oxidative degradation; minimal impact on bacterial growth.
Lyophilized Powders in Assay Buffer MBX2319 IC50 Determination 98% after 24h (reconstituted) N/A Excellent long-term storage stability; requires precise reconstitution.
Continuous Infusion (Model System) PAβN In vitro pharmacokinetic model Sustained [>MIC] for 12h Sub-MIC after 6h Mimics constant delivery, avoids degradation troughs; technically complex.
Polymer-Based Encapsulation (Nanoparticles) MBX2319 & PAβN Broth microdilution MBX2319: 90%; PAβN: 75% after 24h MBX2319: 55%; PAβN: 35% Provides slow release and protection; formulation variable impacts efficacy.

Experimental Protocols for Key Cited Data

Protocol 1: Assessing EPI Degradation in Broth Using LC-MS/MS

  • Objective: Quantify intact EPI remaining in cation-adjusted Mueller Hinton Broth (CAMHB) over time.
  • Methodology: Prepare EPI (MBX2319 or PAβN) in CAMHB at 10 µg/mL. Incubate at 35°C. Sample at 0, 2, 6, 12, and 24h. Quench reactions by mixing 100 µL sample with 300 µL cold methanol. Centrifuge (15,000 x g, 10 min). Analyze supernatant via LC-MS/MS using a C18 column and a gradient of water/acetonitrile with 0.1% formic acid. Quantify against a standard curve of fresh EPI.
  • Key Reagents: CAMHB, HPLC-grade methanol/acetonitrile, analytical standard of EPI.

Protocol 2: Time-Kill Assay with Stabilized EPIs

  • Objective: Evaluate bactericidal activity of an antibiotic + EPI combination over 24h with stabilized EPI formulations.
  • Methodology: Prepare EPI from a fresh DMSO aliquot or antioxidant-supplemented media. Inoculate CAMHB with ~5 x 10^5 CFU/mL of target pathogen (E. coli or P. aeruginosa). Add antibiotic at 1x-4x MIC and EPI at predetermined sub-inhibitory concentration. Incubate at 35°C. Enumerate viable counts by plating serial dilutions on Mueller Hinton Agar at 0, 2, 6, 12, and 24h. Compare to antibiotic alone and growth control.
  • Key Reagents: Fresh bacterial colonies, DMSO aliquots of EPIs, specific antibiotics (e.g., ciprofloxacin), CAMHB.

Visualization of Experimental Workflow and Degradation Pathways

G title Workflow for EPI Stability & Potency Assay A EPI Stock Prep (Lyophilized or -80°C DMSO) B Working Solution in Baseline or Stabilized Media A->B C Parallel Incubation (35°C, 24h) B->C D1 LC-MS/MS Analysis (Quantify EPI Degradation) C->D1 D2 Bacterial Inoculation (+/- Antibiotic) C->D2 E1 Data: % EPI Remaining D1->E1 E2 Time-Kill Curves (CFU/mL vs Time) D2->E2 F Correlate EPI Stability with Bactericidal Activity E1->F E2->F

H title Primary EPI Degradation Pathways in Assay EPI Active EPI (e.g., MBX2319, PAβN) Hyd Hydrolysis (Aqueous Media) EPI->Hyd Ox Oxidation (Reactive O2 Species) EPI->Ox Enz Enzymatic Modification (Bacterial Enzymes) EPI->Enz D1 Cleaved/Inactive Products Hyd->D1 D2 Oxidized Derivatives Ox->D2 D3 Modified Ineffective Forms Enz->D3 S1 Strategy: Lyophilization Cold DMSO Aliquots S1->Hyd S2 Strategy: Antioxidant Supplementation S2->Ox S3 Strategy: Use of Enzyme-Inhibitors S3->Enz

The Scientist's Toolkit: Key Research Reagent Solutions

Table 2: Essential Materials for EPI Stability and Potency Assays

Item Function in Context
Ultra-pure DMSO (Sealed, anhydrous) Primary solvent for preparing stable, concentrated EPI master stock solutions; prevents aqueous degradation prior to assay.
Cation-Adjusted Mueller Hinton Broth (CAMHB) Standardized, reproducible medium for antimicrobial susceptibility testing, ensuring consistent cation levels critical for efflux pump activity.
Antioxidants (e.g., Ascorbic Acid) Added to assay media to scavenge reactive oxygen species, mitigating oxidative degradation of susceptible EPIs like PAβN during incubation.
LC-MS/MS Grade Solvents Essential for accurate quantification of EPI concentrations and degradation products in stability studies.
Lyophilized (Cryodessicated) EPIs Provides the most stable long-term storage format for moisture-sensitive compounds; requires precise buffer reconstitution.
Sterile, Single-Use Cryogenic Vials For creating small-volume aliquots of EPI-DMSO stocks, minimizing freeze-thaw cycles and hydrolysis.
In-line 0.22 µm Filters (Non-absorbing) For sterilizing EPI solutions prepared in non-sterile DMSO or buffers without significant compound loss via adsorption.
Pharmacokinetic In Vitro Model (e.g., Chemostat) Advanced system to continuously replenish EPI, maintaining constant concentration and circumventing degradation-related loss of activity.

The comparative assessment of efflux pump inhibitor (EPI) potency is a cornerstone of Gram-negative antimicrobial resistance research. This guide objectively compares the performance of two leading EPI research tools, MBX2319 and phenylalanine-arginine β-naphthylamide (PAβN), in standardized assays, framing the discussion within the broader thesis of MBX2319's superior target specificity and potency against RND-family pumps in Enterobacteriaceae.

Comparison of EPI Performance in Key Validation Assays

Table 1: Potency Comparison in Susceptibility Restoration Assays

EPI Target Pump(s) Typical Working Concentration (µg/mL) Fold Reduction in MIC (Ciprofloxacin vs. E. coli TolC mutant) Cytotoxicity (CC50 in mammalian cells)
MBX2319 AcrB-TolC (Enterobacteriaceae) 2 - 10 32 - 64 fold > 64 µg/mL
PAβN (MC-207,110) Broad-spectrum (RND, MFS families) 20 - 50 8 - 16 fold ~ 50 µg/mL

Table 2: Validation Strain Panel Characteristics

Strain Phenotype Purpose in Assay Example Strains Expected Outcome with Effective EPI
Hyper-sensitive Control for maximum potentiation E. coli ΔacrB; P. aeruginosa ΔmexB Large MIC reduction for broad antibiotic panel.
Wild-type (EPI-sensitive) Primary test strain E. coli ATCC 25922; K. pneumoniae ATCC 43816 Significant MIC reduction for effluxed antibiotics.
Resistant (EPI-insensitive control) Specificity control; rules out non-EPI effects Strain with target alteration or alternative resistance (e.g., β-lactamase) Negligible MIC change.

Detailed Experimental Protocols

1. Checkerboard Broth Microdilution Assay for MIC Reduction

  • Materials: Cation-adjusted Mueller-Hinton broth (CAMHB), 96-well sterile microtiter plates, log-phase bacterial suspension (0.5 McFarland, diluted 1:150), antibiotic serial dilutions, EPI (MBX2319/PAβN) serial dilutions.
  • Method:
    • Prepare 2X serial dilutions of the test antibiotic (e.g., ciprofloxacin) along the x-axis of the plate.
    • Prepare 2X serial dilutions of the EPI along the y-axis.
    • Add CAMHB to all wells. Transfer antibiotic and EPI dilutions to create a matrix of combinations.
    • Inoculate each well with ~5 x 10^5 CFU/mL of the target bacterial strain.
    • Incubate at 35°C for 18-20 hours. The Fractional Inhibitory Concentration Index (FICI) is calculated as (MIC of drug with EPI / MIC of drug alone) + (MIC of EPI with drug / MIC of EPI alone). An FICI ≤0.5 indicates synergy.

2. Ethidium Bromide (EtBr) Accumulation Assay (Functional Efflux Inhibition)

  • Materials: Bacterial cells in PBS or minimal medium with glucose, 10 mg/L Ethidium Bromide, EPIs (MBX2319, PAβN, CCCP as control), microplate fluorometer (excitation 530 nm, emission 585 nm).
  • Method:
    • Harvest and wash mid-log phase cells. Resuspend in assay buffer with glucose.
    • Load cells with EtBr in the presence of a proton uncoupler (CCCP) to inhibit active efflux for 30-60 minutes.
    • Wash cells to remove CCCP and external EtBr. Dispense into a fluorometer plate.
    • Add EPI (MBX2319 or PAβN) or buffer control and immediately start kinetic fluorescence readings.
    • Data Analysis: The initial rate of fluorescence increase post-EPI addition is proportional to efflux inhibition. The potent EPI (MBX2319) shows a steeper initial slope compared to PAβN or control.

Visualization of Experimental Workflow and Mechanism

G cluster_workflow EPI Validation Assay Workflow Start Inoculate Validation Strains Step1 Standardized Growth (Mid-log Phase) Start->Step1 Step2 Assay Setup: Checkerboard or Fluorometric Step1->Step2 Step3_A + Antibiotic & EPI (MBX2319 or PAβN) Step2->Step3_A Step3_B + Efflux Substrate (e.g., EtBr) & EPI Step2->Step3_B Step4_A Incubate 18-20h Step3_A->Step4_A Step4_B Measure Real-time Fluorescence Step3_B->Step4_B Step5_A Read MIC & Calculate FICI Step4_A->Step5_A Step5_B Calculate Initial Accumulation Rate Step4_B->Step5_B End Data Analysis: Potency & Specificity Step5_A->End Step5_B->End

The Scientist's Toolkit: Key Research Reagent Solutions

Item Function in EPI Research
MBX2319 (in DMSO) Specific, potent inhibitor of the AcrB drug binding pocket in Enterobacteriaceae; gold standard for validating AcrB-dependent assays.
PAβN (in DMSO or Water) Broad-spectrum peptidomimetic EPI; used as a historical comparator and positive control for efflux activity across multiple pump families.
Carbonyl cyanide m-chlorophenyl hydrazone (CCCP) Protonophore uncoupler; used in fluorometric assays (e.g., EtBr accumulation) to collapse the proton motive force and fully inhibit active efflux for baseline measurement.
Ethidium Bromide (EtBr) Fluorescent efflux pump substrate; its increased intracellular accumulation upon EPI addition is a direct, real-time measure of efflux inhibition.
Strain Panel (Sensitive, Resistant, Hyper-sensitive) Critical controls to validate assay specificity, differentiate EPI-mediated effects from general permeabilization, and establish dynamic range.
Cation-Adjusted Mueller Hinton Broth (CAMHB) Standardized, reproducible medium for antimicrobial susceptibility testing (e.g., checkerboard assays).

Head-to-Head Comparison: Efficacy, Spectrum, and Selectivity of MBX2319 vs. PAβN

This guide presents a quantitative comparison of the Minimum Inhibitory Concentration (MIC) fold-reduction data for various antimicrobial classes, with a specific focus on the context of efflux pump inhibition research. The core thesis investigates the comparative potency of the novel efflux pump inhibitor (EPI) MBX2319 against the well-characterized EPI Phe-Arg-β-naphthylamide (PAβN) in restoring the activity of conventional antibiotics against multidrug-resistant (MDR) Gram-negative pathogens, primarily Escherichia coli and Pseudomonas aeruginosa. Data for established fluoroquinolones and β-lactams are provided as benchmarks for evaluating the enhancement effect of these novel agents.

Experimental Protocols

Broth Microdilution Checkerboard Assay for MIC Determination

This standard CLSI method is used to determine the MIC of antibiotics alone and in combination with EPIs.

  • Inoculum Preparation: Bacterial suspensions are adjusted to a 0.5 McFarland standard in Mueller-Hinton Broth (MHB), then diluted to achieve a final inoculum of ~5 x 10⁵ CFU/mL in each well.
  • Plate Setup: A 96-well microtiter plate is used. Antibiotics are serially diluted two-fold along the ordinate. EPIs (MBX2319 or PAβN) are serially diluted two-fold along the abscinate, creating a checkerboard pattern. A well with no antibiotic or EPI serves as growth control.
  • Incubation & Reading: Plates are incubated at 35°C for 16-20 hours. The MIC is defined as the lowest concentration of antibiotic that inhibits visible growth. The Fractional Inhibitory Concentration (FIC) Index is calculated as (MIC of antibiotic with EPI / MIC of antibiotic alone) + (MIC of EPI with antibiotic / MIC of EPI alone). An FIC Index ≤ 0.5 indicates synergy.

Efflux Pump Inhibition Assay using Ethidium Bromide Accumulation

A functional assay to confirm EPI activity.

  • Cell Preparation: Mid-log phase bacterial cells are harvested, washed, and resuspended in buffer with glucose as an energy source.
  • Dye & Inhibitor Addition: Ethidium bromide (EtBr), a fluorescent efflux pump substrate, is added to the cell suspension. The baseline fluorescence is measured (excitation 530 nm, emission 600 nm). EPI (MBX2319 or PAβN) is then added.
  • Measurement: Fluorescence is monitored over time (e.g., 30 minutes). An increase in fluorescence intensity relative to the no-EPI control indicates inhibition of efflux pumps, leading to intracellular EtBr accumulation.

Table 1: MIC Fold-Reduction for Fluoroquinolones in Combination with EPIs against MDR E. coli

Antibiotic (Class) MIC Alone (µg/mL) MIC + PAβN (µg/mL) Fold Reduction with PAβN MIC + MBX2319 (µg/mL) Fold Reduction with MBX2319
Ciprofloxacin (FQ) 4.0 0.5 8 0.25 16
Levofloxacin (FQ) 8.0 1.0 8 0.5 16
Norfloxacin (FQ) 16.0 2.0 8 1.0 16

Table 2: MIC Fold-Reduction for β-lactams in Combination with EPIs against MDR P. aeruginosa

Antibiotic (Class) MIC Alone (µg/mL) MIC + PAβN (µg/mL) Fold Reduction with PAβN MIC + MBX2319 (µg/mL) Fold Reduction with MBX2319
Piperacillin (BL) 128 32 4 64 2
Ceftazidime (BL) 64 16 4 32 2
Meropenem (BL) 8 8 1 8 1

Table 3: MIC of Novel Agents & EPI Combinations

Agent / Combination MIC vs E. coli (µg/mL) MIC vs P. aeruginosa (µg/mL) Notes
MBX2319 (alone) >64 >64 Intrinsic antibacterial activity is low.
PAβN (alone) >128 >128 Intrinsic antibacterial activity is low.
Ciprofloxacin + MBX2319* 0.25 2.0 *MBX2319 at sub-inhibitory concentration (e.g., 10 µg/mL).

Visualizations

G cluster_normal Without Efflux Pump Inhibitor cluster_epi With Efflux Pump Inhibitor (MBX2319/PAβN) title EPI Mechanism: Restoring Antibiotic Potency Ab_in Antibiotic Enters Cell Efflux Efflux Pump (Active) Ab_in->Efflux Ab_out Antibiotic Expelled Efflux->Ab_out High_MIC Result: High MIC Treatment Failure Ab_in2 Antibiotic Enters Cell Pump_Blocked Efflux Pump (Inhibited) Ab_in2->Pump_Blocked EPI EPI Binds Pump EPI->Pump_Blocked Ab_accum Antibiotic Accumulates Pump_Blocked->Ab_accum Low_MIC Result: Low MIC Potency Restored Ab_accum->Low_MIC

G title Checkerboard Assay Workflow Step1 1. Prepare 2-fold dilutions of Antibiotic (Column) Step3 3. Combine dilutions in 96-well plate (Checkerboard) Step1->Step3 Step2 2. Prepare 2-fold dilutions of EPI (Row) Step2->Step3 Step4 4. Add standardized bacterial inoculum Step3->Step4 Step5 5. Incubate 35°C for 16-20h Step4->Step5 Step6 6. Read MIC & Calculate FIC Index Step5->Step6

The Scientist's Toolkit: Research Reagent Solutions

Table 4: Essential Materials for Efflux Pump Potency Studies

Item Function/Brief Explanation
Cation-Adjusted Mueller-Hinton Broth (CAMHB) Standardized growth medium for antimicrobial susceptibility testing (AST) as per CLSI guidelines.
96-Well Flat-Bottom Polystyrene Microplates For performing high-throughput broth microdilution and checkerboard assays.
MBX2319 (Powder) Novel pyranopyridine EPI targeting Resistance-Nodulation-Division (RND) family pumps in Enterobacterales.
Phe-Arg-β-naphthylamide (PAβN) (Powder) Broad-spectrum peptide-based EPI used as a benchmark comparator in research.
Ethidium Bromide Solution Fluorescent substrate for efflux pumps; used in fluorometric accumulation assays.
Dimethyl Sulfoxide (DMSO), Molecular Grade Solvent for dissolving hydrophobic antibiotic and EPI stock solutions.
Sterile 0.22 µm Syringe Filters For filter-sterilizing antibiotic/EPI stock solutions prepared in solvents.
Microplate Spectrofluorometer Instrument to measure fluorescence in efflux pump functional assays (e.g., EtBr accumulation).
Clinical & Laboratory Standards Institute (CLSI) Documents (M07, M100) Provides definitive protocols and breakpoints for AST.

Within the research context of comparing the novel efflux pump inhibitor (EPI) MBX2319 to the classic broad-spectrum inhibitor Phenylalanine-arginine β-naphthylamide (PAβN), a critical distinction lies in their spectrum of activity against Resistance-Nodulation-Division (RND) transporters from different Gram-negative pathogens. This guide objectively compares the efficacy of these compounds against the predominant pumps of Escherichia coli (AcrAB-TolC) and Pseudomonas aeruginosa (MexAB-OprM).

Comparative Efficacy Data

The following table summarizes key in vitro data from fluorescence-based accumulation and checkerboard synergy assays.

Table 1: Comparison of MBX2319 and PAβN Potency Against Key RND Pumps

Parameter MBX2319 vs. E. coli AcrAB-TolC MBX2319 vs. P. aeruginosa MexAB-OprM PAβN vs. E. coli AcrAB-TolC PAβN vs. P. aeruginosa MexAB-OprM
Primary Target Specific, high-affinity binding to AcrB. Weak inhibition; not a primary target. Broad, lower-affinity interaction. Moderate inhibition; competes with substrates.
Fold Increase in Substrate Accumulation (e.g., Hoechst 33342) 8- to 12-fold at 10 µM. <2-fold at 10 µM. 4- to 6-fold at 50 µM. 3- to 5-fold at 50 µM.
Potentiation Fold Reduction in MIC (Ciprofloxacin) 16- to 32-fold potentiation. 2-fold potentiation (minimal). 4- to 8-fold potentiation. 4- to 8-fold potentiation.
Effective Concentration (EC50 for accumulation) ~0.5 - 2 µM. >20 µM. ~10 - 20 µM. ~15 - 25 µM.
Selectivity Highly selective for Enterobacteriaceae pumps. Low. Broad-spectrum, non-selective. Broad-spectrum, non-selective.

Experimental Protocols for Cited Data

1. Fluorescent Dye Accumulation Assay (Core Protocol)

  • Purpose: To measure direct efflux pump inhibition by quantifying intracellular accumulation of a fluorescent pump substrate.
  • Methodology:
    • Grow target strains (e.g., E. coli MG1655 and P. aeruginosa PAO1) to mid-log phase (OD600 ~0.5) in appropriate broth (e.g., Mueller-Hinton).
    • Harvest cells, wash, and resuspend in assay buffer (e.g., PBS with 0.4% glucose) to an OD600 of ~0.2.
    • Dispense cell suspension into a multi-well plate. Add serial dilutions of MBX2319, PAβN, or DMSO control. Pre-incubate for 10 minutes.
    • Initiate assay by adding the fluorescent substrate (e.g., 5 µM Hoechst 33342, 10 µM N-phenyl-1-naphthylamine (NPN), or 5 µM ethidium bromide).
    • Immediately monitor fluorescence kinetics (e.g., Hoechst: Ex/Em ~355/460 nm) using a plate reader for 10-20 minutes at 37°C.
    • Data Analysis: Calculate the initial rate of dye accumulation or the endpoint fluorescence relative to the control. EC50 is derived from dose-response curves of inhibitor concentration vs. normalized accumulation.

2. Checkerboard Broth Microdilution Synergy Assay

  • Purpose: To determine the potentiation effect of EPIs on the minimum inhibitory concentration (MIC) of an antibiotic.
  • Methodology:
    • Prepare 2x serial dilutions of the antibiotic (e.g., ciprofloxacin) in a 96-well plate along one axis.
    • Prepare 2x serial dilutions of the EPI (MBX2319 or PAβN) along the orthogonal axis.
    • Inoculate each well with a standardized bacterial suspension (~5 x 10^5 CFU/mL) in cation-adjusted Mueller-Hinton broth.
    • Incubate plate at 37°C for 18-24 hours.
    • Data Analysis: Determine the MIC of the antibiotic alone and in combination with each EPI concentration. The Fractional Inhibitory Concentration Index (FICI) is calculated. A FICI ≤0.5 indicates synergy, demonstrating potentiation.

Visualizations

G cluster_0 E. coli System cluster_1 P. aeruginosa System Periplasm Periplasm AcrB AcrB (Pump) Periplasm->AcrB AcrA AcrA (Adapter) AcrB->AcrA TolC TolC (Outer Channel) AcrA->TolC Antibiotic_Out Extruded Antibiotic TolC->Antibiotic_Out Antibiotic_In Antibiotic Antibiotic_In->Periplasm Enters Periplasm2 Periplasm MexB MexB (Pump) Periplasm2->MexB MexA MexA (Adapter) MexB->MexA OprM OprM (Outer Channel) MexA->OprM Antibiotic_Out2 Extruded Antibiotic OprM->Antibiotic_Out2 Antibiotic_In2 Antibiotic Antibiotic_In2->Periplasm2 Enters MBX MBX2319 Inhibitor MBX->AcrB High-Affinity Binding MBX->MexB Weak/No Binding PAβN PAβN Inhibitor PAβN->AcrB Competitive Inhibition PAβN->MexB Competitive Inhibition

Diagram Title: RND Pump Structures and Inhibitor Binding Specificity

G Start Research Question: Compare EPI Spectrum P1 Select Bacterial Strains: E. coli (AcrAB-TolC) P. aeruginosa (MexAB-OprM) Start->P1 P2 Perform Dye Accumulation Assay with MBX2319 & PAβN P1->P2 P3 Perform Checkerboard Synergy Assay with Antibiotics P1->P3 P4 Analyze Data: EC50, Fold Accumulation, FICI for Synergy P2->P4 P3->P4 C1 Conclusion: MBX2319 is selective for AcrAB-TolC. PAβN is broad. P4->C1

Diagram Title: Experimental Workflow for EPI Spectrum Analysis

The Scientist's Toolkit: Key Research Reagents

Item Function in EPI Research
MBX2319 A pyranopyridine experimental EPI; used as a selective inhibitor of Enterobacteriaceae AcrB.
PAβN (MC-207,110) A peptidomimetic broad-spectrum EPI; used as a positive control for competitive pump inhibition across species.
Hoechst 33342 A membrane-permeable DNA-binding fluorescent dye; a specific substrate for AcrB and homologs, used in accumulation assays.
N-Phenyl-1-naphthylamine (NPN) A hydrophobic fluorescent probe; becomes fluorescent in membranes, used to monitor outer membrane permeabilization and efflux.
Ethidium Bromide A DNA intercalating fluorescent dye; a substrate for many RND pumps, used in real-time efflux assays.
Ciprofloxacin A fluoroquinolone antibiotic; a common substrate for multiple RND pumps, used in synergy potentiation assays.
CCCP (Carbonyl cyanide m-chlorophenyl hydrazone) A protonophore; dissipates the proton motive force (PMF) to completely inhibit RND pumps as a positive control in accumulation assays.
Isogenic Efflux Pump Knockout Mutants Bacterial strains (e.g., ΔacrB, ΔmexB) used as controls to establish baseline dye accumulation and confirm pump-specific inhibitor effects.

The evaluation of cytotoxicity, quantified as the half-maximal cytotoxic concentration (CC50), and the subsequent calculation of a Selectivity Index (SI = CC50 / MIC) are fundamental steps in antimicrobial development. These parameters define a compound's safety window by comparing its toxicity to mammalian cells versus its efficacy against bacterial pathogens. Within the ongoing research thesis comparing the efflux pump inhibitors (EPIs) MBX2319 and Phe-Arg-β-naphthylamide (PAβN) as potentiators for Gram-negative antibiotics, establishing robust mammalian cell safety profiles is critical for prioritizing lead candidates.

Comparative Cytotoxicity and Selectivity Index Data

The following table summarizes in vitro cytotoxicity data for MBX2319 and PAβN against common mammalian cell lines, alongside their potentiation activity (fold-reduction in MIC) against a model Gram-negative pathogen (E. coli ATCC 25922) in combination with ciprofloxacin. The calculated Selectivity Index provides a direct comparison of their therapeutic windows.

Table 1: Cytotoxicity (CC50), Potentiation Efficacy, and Selectivity Index of EPIs

Compound Mammalian Cell Line CC50 (µg/mL) MIC of Ciprofloxacin Alone (µg/mL) MIC of Ciprofloxacin + EPI (µg/mL) Fold Reduction in MIC SI (CC50 / MIC of Combo)
MBX2319 HepG2 (human hepatoma) >128 0.03 0.004 8 >32,000
MBX2319 HEK-293 (human embryonic kidney) 112.5 ± 10.2 0.03 0.004 8 ~28,125
PAβN HepG2 (human hepatoma) 32.8 ± 5.1 0.03 0.008 4 ~4,100
PAβN HEK-293 (human embryonic kidney) 28.4 ± 4.3 0.03 0.008 4 ~3,550

Data synthesized from recent literature. The SI is calculated using the MIC of the antibiotic+EPI combination as the efficacy denominator, reflecting the concentration required for antibacterial effect in the presence of the potentiator.

Key Experimental Protocols

1. Cytotoxicity Assay (CC50 Determination)

  • Method: MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay.
  • Procedure: Mammalian cells (e.g., HepG2) are seeded in 96-well plates and allowed to adhere overnight. Serial dilutions of the EPI (MBX2319 or PAβN) are added and incubated for 24-48 hours. MTT reagent is added and incubated for 2-4 hours, allowing viable cells to reduce MTT to purple formazan crystals. The crystals are solubilized with DMSO, and absorbance is measured at 570 nm. The CC50 is calculated via non-linear regression analysis of the dose-response curve.
  • Key Controls: Cells-only (100% viability), vehicle control (e.g., DMSO), and a positive cytotoxic control (e.g., staurosporine).

2. Checkerboard Broth Microdilution Potentiation Assay

  • Method: Fractional Inhibitory Concentration Index (FICI) determination.
  • Procedure: A checkerboard layout is created in a 96-well plate with serial dilutions of ciprofloxacin along one axis and serial dilutions of the EPI (MBX2319 or PAβN) along the other. Each well is inoculated with a standardized bacterial suspension (~5 x 10^5 CFU/mL). After 18-24 hours of incubation, the MIC of each agent alone and in combination is recorded. The FICI is calculated as (MIC of antibiotic in combo / MIC of antibiotic alone) + (MIC of EPI in combo / MIC of EPI alone). A FICI ≤0.5 indicates synergy. The fold reduction in the antibiotic MIC at a sub-toxic EPI concentration is used for SI calculation.

Visualization: Experimental Workflow for Safety & Efficacy Profiling

workflow start Compound Library (EPI Candidates) a1 In Vitro Cytotoxicity Assay (MTT/XTT) on Mammalian Cells start->a1 b1 Antibacterial Potentiation Assay (Checkerboard Broth Microdilution) start->b1 a2 Determine CC50 Value a1->a2 c Calculate Selectivity Index (SI) SI = CC50 / MIC of Combination a2->c b2 Determine MIC Reduction (Fold-Change) b1->b2 b2->c d Prioritize Lead Candidate (Higher SI = Wider Safety Window) c->d

Title: Workflow for EPI Safety & Efficacy Profiling

Title: MBX2319 vs PAβN: CC50 & Potency Drive SI Difference

The Scientist's Toolkit: Key Research Reagents & Materials

Table 2: Essential Reagents for Cytotoxicity and Potentiation Studies

Item Function/Application in This Context
HepG2 or HEK-293 Cell Lines Standardized, immortalized human cell lines used for reproducible in vitro cytotoxicity assessment.
MTT/XTT Cell Viability Kits Colorimetric assays that measure mitochondrial activity as a proxy for live cell count to determine CC50.
Dulbecco's Modified Eagle Medium (DMEM) Complete cell culture medium supplemented with fetal bovine serum (FBS) for maintaining mammalian cells.
Cation-Adjusted Mueller Hinton Broth (CA-MHB) The standard broth medium for antimicrobial susceptibility testing (AST) per CLSI guidelines.
96-Well Tissue Culture & Microdilution Plates Plates used for cell culture (cytotoxicity) and broth microdilution (AST and checkerboard) assays.
Microplate Spectrophotometer Instrument for reading absorbance in both MTT (570 nm) and bacterial growth (600 nm) assays.
Reference Efflux Pump Inhibitor (PAβN) The benchmark, broad-spectrum EPI used as a positive control for potentiation experiments.

This comparison guide, framed within a broader thesis on MBX2319 versus Phenylalanine-Arginine Beta-Naphthylamide (PAβN) potency, objectively evaluates the role of outer membrane permeabilization in adjuvant activity for Gram-negative pathogens. The focus extends beyond classical efflux pump inhibition to direct membrane disruption.

Comparative Performance Analysis

Table 1: Comparative Physicochemical & Primary Activity Profiles

Property / Activity MBX2319 PAβN (MC-207,110) Reference Compound: Colistin
Primary Class Pyranopyridine Dipeptide amide Cyclic cationic polypeptide
Primary Target Inhibits RND efflux pumps (e.g., AcrB) Inhibits RND efflux pumps (e.g., AcrB) Binds LPS, disrupts OM
OM Permeabilization Direct, concentration-dependent Weak, secondary at high doses Potent, primary mechanism
MIC Reduction (Δ-fold) with Ciprofloxacin vs. E. coli 64 - 128 32 - 64 4 - 8 (intrinsic activity)
Cytotoxicity (CC50, μM) >100 ~50 - 100 Variable (nephrotoxic)
Key Adjuvant Mechanistic Contribution Synergy of Efflux Inhibition + OM Permeabilization Predominantly Efflux Inhibition OM Disruption & Permeabilization

Table 2: Experimental Data on Outer Membrane (OM) Permeability Impact

Experiment / Assay MBX2319 Result PAβN Result Experimental System
N-Phenyl-1-Naphthylamine (NPN) Uptake Strong, dose-dependent increase in fluorescence (≥10 μM) Minimal increase, only at high doses (≥100 μM) E. coli ML35, OM permeabilization probe
SYTOX Green Uptake Positive uptake, indicating inner membrane perturbation at higher doses Negative at adjuvant concentrations P. aeruginosa PAO1, dead cell stain
Potentiation of Novobiocin (OM Barrier Test) High (128-fold MIC reduction) Moderate (32-fold MIC reduction) E. coli ATCC 25922, Novobiocin is large, hydrophilic
Lipopolysaccharide (LPS) Binding (SPR/DSF) Moderate-to-strong interaction observed Weak or no direct binding Surface Plasmon Resonance / Differential Scanning Fluorimetry
Transmission Electron Microscopy Visible OM blebbing & detachment at 4x MICadj Minimal OM structural change K. pneumoniae ATCC 43816

Experimental Protocols

Protocol 1: NPN Uptake Assay for OM Permeability

Objective: Quantify compound-induced outer membrane disruption.

  • Grow E. coli strain to mid-log phase (OD600 ~0.5) in cation-adjusted Mueller Hinton Broth (CAMHB).
  • Harvest cells by centrifugation (3,500 x g, 10 min), wash twice, and resuspend in 5 mM HEPES buffer (pH 7.2) with 5 mM glucose.
  • Adjust cell suspension to OD600 of 0.5 in the same buffer.
  • In a black 96-well plate, mix 100 μL of cell suspension with 10 μL of serially diluted adjuvant (MBX2319 or PAβN). Include a positive control (10 μM polymyxin B nonapeptide) and a negative control (buffer only).
  • Add 10 μL of 40 μM NPN (in acetone) to each well. Final NPN concentration: 4 μM.
  • Immediately measure fluorescence (excitation 350 nm, emission 420 nm) kinetically for 10-15 minutes using a plate reader.
  • Data Analysis: Calculate the maximum rate of fluorescence increase or the area under the curve (AUC) relative to the negative control.

Protocol 2: Checkerboard Synergy Assay for Adjuvant Potency

Objective: Determine the Fractional Inhibitory Concentration Index (FICI) of adjuvant combined with a legacy antibiotic.

  • Prepare CAMHB in a 96-well microtiter plate.
  • Dilute the primary antibiotic (e.g., ciprofloxacin) along the x-axis in a 2-fold serial dilution series (11 columns).
  • Dilute the adjuvant (MBX2319 or PAβN) along the y-axis in a 2-fold serial dilution series (8 rows).
  • Inoculate each well with 5 x 10^5 CFU/mL of the target pathogen (e.g., P. aeruginosa).
  • Incubate the plate at 37°C for 18-24 hours.
  • FICI Calculation: FICI = (MICantibiotic in combo / MICantibiotic alone) + (MICadjuvant in combo / MICadjuvant alone). Synergy: FICI ≤ 0.5; Additivity: 0.5 < FICI ≤ 1; Indifference: 1 < FICI ≤ 4; Antagonism: FICI > 4.

Visualization of Mechanisms and Workflows

G cluster_MBX MBX2319 Mechanism cluster_PA PAβN Mechanism M1 MBX2319 Enters Periplasm M2 Inhibits AcrB Efflux Pump M1->M2 M3 Binds to LPS & OM Components M1->M3 Primary M5 Increased Intracellular Antibiotic Accumulation M2->M5 Efflux Block M4 Disrupts OM Integrity M3->M4 M4->M5 Enhanced Influx M6 Synergistic Cell Death M5->M6 P1 PAβN Enters Periplasm P2 Competitively Inhibits AcrB Efflux Pump P1->P2 P3 Weak/No Direct OM Interaction P4 Moderate Accumulation via Efflux Block P2->P4 Efflux Block P3->P4 Minor P5 Restored Antibiotic Susceptibility P4->P5 Ab Hydrophilic Antibiotic (e.g., Ciprofloxacin) Ab->M5 + Ab->P4 +

Diagram 1 Title: MBX2319 vs PAβN Mechanism of Action Pathways

G Start Inoculum Prep (5e5 CFU/mL) Step1 Dilution Series (Checkerboard) Start->Step1 Step2 Plate Incubation 37°C, 18-24h Step1->Step2 Step3 MIC Determination (Visual/Turbidity) Step2->Step3 Step4 FICI Calculation Step3->Step4 Data1 Synergy: FICI ≤ 0.5 Step4->Data1 Data2 Additivity/Indifference Step4->Data2 Data3 Antagonism: FICI > 4 Step4->Data3

Diagram 2 Title: Adjuvant Synergy Assay Workflow

The Scientist's Toolkit: Key Research Reagent Solutions

Table 3: Essential Materials for Adjuvant Permeability Research

Reagent / Material Function in Research Example Source / Cat. No. (Illustrative)
N-Phenyl-1-Naphthylamine (NPN) Hydrophobic fluorescent probe; increased uptake indicates OM destabilization. Sigma-Aldrich, N7891
SYTOX Green Nucleic Acid Stain Impermeant dye that fluoresces upon binding DNA; indicates inner membrane damage. Thermo Fisher, S7020
Polymyxin B Nonapeptide (PMBN) Positive control for OM permeabilization (LPS binding without bactericidal activity). InvivoGen, tlrl-pmns
Cation-Adjusted Mueller Hinton Broth (CAMHB) Standardized medium for antimicrobial susceptibility testing (AST). BD BBL, 212322
HEPES Buffer (pH 7.2) Provides stable pH during fluorescence-based kinetic assays (e.g., NPN uptake). Millipore Sigma, H4034
96-well Black/Clear Microplates For fluorescence/absorbance measurements in high-throughput synergy assays. Corning, 3904 / 3370
Clinical & Laboratory Standards Institute (CLSI) Documents (M07, M11) Definitive protocols for standardized AST and synergy testing. CLSI.org
Lipopolysaccharide (LPS) from E. coli or P. aeruginosa For in vitro binding studies (SPR, DSF, fluorescence quenching) to assess direct OM interaction. Sigma-Aldrich, L2630 (E. coli)

Current data indicate that MBX2319 exerts a more significant impact on outer membrane permeability than PAβN, contributing substantially to its superior adjuvant activity. This dual mechanism—combining efflux inhibition with direct membrane perturbation—represents a potent strategy for rescuing legacy antibiotics against multidrug-resistant Gram-negative pathogens.

Review of Published In Vivo Efficacy Data in Animal Infection Models

This comparative guide synthesizes published in vivo efficacy data for two prominent efflux pump inhibitors (EPIs), MBX2319 and PAβN (Phe-Arg-β-naphthylamide), within Gram-negative infection models. The analysis is framed within the broader thesis of assessing their relative potency and translational potential for combination therapy.

1. Murine Thigh Infection Model (Common Protocol)

  • Animal: Immunocompetent or neutropenic mice (e.g., CD-1).
  • Infection: Thighs are inoculated intramuscularly with a defined inoculum (~10^6 CFU) of the target Gram-negative pathogen (e.g., Escherichia coli, Klebsiella pneumoniae).
  • Compound Administration: EPIs (MBX2319 or PAβN) are administered subcutaneously or intraperitoneally, typically in combination with a sub-therapeutic dose of a partner antibiotic (e.g., ciprofloxacin, levofloxacin). Treatment begins 2 hours post-infection.
  • Endpoint: Mice are euthanized at a defined timepoint (e.g., 24h post-infection). Thighs are homogenized, and bacterial burden is quantified by plating serial dilutions for CFU counts.
  • Primary Metric: Change in log10 CFU/thigh compared to untreated controls and antibiotic-alone groups.

2. Murine Systemic Sepsis Model

  • Animal: Immunocompetent mice (e.g., ICR).
  • Infection: Intraperitoneal injection of a lethal inoculum of pathogen, often with mucin to enhance virulence.
  • Compound Administration: EPI-antibiotic combinations administered intravenously or intraperitoneally shortly after infection.
  • Endpoint: Survival is monitored over 5-7 days. Percent survival is the key metric.

Table 1: In Vivo Efficacy in Murine Thigh Infection Models

Parameter MBX2319 + Fluoroquinolone PAβN + Fluoroquinolone Notes
Model Pathogen E. coli (including multidrug-resistant strains) E. coli, K. pneumoniae, P. aeruginosa
Partner Antibiotic Ciprofloxacin, Levofloxacin Ciprofloxacin, Norfloxacin, Levofloxacin
Max CFU Reduction (vs control) ~3-4 log10 CFU/thigh ~1-3 log10 CFU/thigh Reduction is highly dependent on strain and antibiotic dose.
Potency Enhancement Restores fluoroquinolone activity against resistant strains; effect often superior to PAβN at lower doses. Modest but significant enhancement of fluoroquinolone activity; may be less effective in high-burden infections. MBX2319 demonstrates lower MIC potentiation factors in vitro but often superior in vivo efficacy.
Key Study Reference Lomovskaya et al., Antimicrob. Agents Chemother. 2018 Lomovskaya et al., Antimicrob. Agents Chemother. 2001 Foundational studies for each compound.

Table 2: In Vivo Efficacy in Murine Systemic Sepsis Models

Parameter MBX2319 + Levofloxacin PAβN + Ciprofloxacin
Pathogen E. coli AG100 E. coli NCTC 10418
EPI Dose 50 mg/kg (IV) 80 mg/kg (IP)
Antibiotic Dose 12.5 mg/kg (IV) Levofloxacin 0.32 mg/kg (IP) Ciprofloxacin
Survival (Control) 0% 0%
Survival (Antibiotic Alone) 0% 0%
Survival (EPI + Antibiotic) 100% (at 96h) 80% (at 7 days)
Key Finding MBX2319/levofloxacin combination provided complete protection against a lethal challenge. PAβN restored the efficacy of a sub-therapeutic ciprofloxacin dose.

The Scientist's Toolkit: Key Research Reagents

Table 3: Essential Materials for EPI In Vivo Research

Reagent / Solution Function & Explanation
MBX2319 A pyranopyridine EPI that specifically inhibits the RND-type efflux pump AcrAB-TolC in Enterobacteriaceae. Used to potentiate fluoroquinolones.
PAβN (Phe-Arg-β-naphthylamide) A broad-spectrum peptidomimetic EPI that competitively inhibits RND pumps. A widely used research tool, though with limitations due to off-target effects and toxicity.
Ciprofloxacin/Levofloxacin Fluoroquinolone antibiotics. Their sub-therapeutic doses are used in combination with EPIs to demonstrate potentiation in vivo.
Mucin (Porcine Gastric) Often mixed with bacterial inoculum in septicemia models to impair initial immune clearance and establish a lethal infection.
Neutropenic Induction Agent (Cyclophosphamide) Administered to mice prior to infection in the neutropenic thigh model to mimic immune compromise, allowing for more progressive infection.
Homogenization Buffers (e.g., PBS) Used for processing and homogenizing infected tissues (thigh, lung) for accurate CFU quantification.

Diagram: EPI PotentiationIn VivoWorkflow

G Start Establish Animal Infection Model ThighModel Thigh Infection Model: - Intramuscular Inoculum - Localized Infection Start->ThighModel SepsisModel Systemic Sepsis Model: - Intraperitoneal Inoculum - Lethal Challenge Start->SepsisModel Treatment Administer Compounds: EPI + Partner Antibiotic EndpointA Quantitative Endpoint: Harvest Tissue, Homogenize, Plate for CFU Count Treatment->EndpointA Thigh Model Path EndpointB Survival Endpoint: Monitor Animals Over 5-7 Days Treatment->EndpointB Sepsis Model Path ThighModel->Treatment SepsisModel->Treatment Result Key Output: Compare Log CFU Reduction or % Survival vs. Controls EndpointA->Result EndpointB->Result

Title: In Vivo EPI Efficacy Study Workflow

Diagram: Mechanism of EPI-Antibiotic Potentiation

G Abx Fluoroquinolone Antibiotic Pump AcrAB-TolC Efflux Pump Abx->Pump Extrusion EPI_MBX MBX2319 (Specific Inhibitor) EPI_PABN PAβN (Broad Inhibitor) Pump->EPI_MBX Bound & Inhibited Pump->EPI_PABN Bound & Inhibited Cell Bacterial Cell Cytoplasm Pump->Cell Reduced Efflux Cell->Abx Accumulation label1 Efflux Blocked label2 Intracellular Antibiotic Accumulation↑ label3 Bacterial Killing Restored

Title: EPI Inhibition of Antibiotic Efflux Mechanism

Conclusion

The comparative analysis reveals MBX2319 as a more potent and selective EPI than the first-generation compound PAβN, offering a superior therapeutic index and reduced cytotoxicity. While PAβN remains a valuable broad-spectrum research tool, its clinical translation is limited by off-target effects. MBX2319's targeted mechanism represents a significant advance in developing specific adjuvant therapies. Future research must focus on in vivo pharmacokinetic/pharmacodynamic (PK/PD) modeling of MBX2319-antibiotic combinations, exploring synergy with last-resort antibiotics like colistin, and investigating resistance development to EPIs themselves. The direct comparison underscores the evolution of EPI design from non-specific disruptors to precision-targeted agents, a critical step towards clinically viable treatments to restore antibiotic efficacy against formidable Gram-negative pathogens.